{"products":[{"id":7729560387671,"title":"Bacteriostatic Water","handle":"bacteriostatic-water","body_html":"\u003cp\u003eBacteriostatic water is the standard diluent used to reconstitute lyophilised research peptides. Each multi-dose vial contains 10 mL of water with \u003cstrong\u003e0.9% benzyl alcohol (9 mg\/mL)\u003c\/strong\u003e as a bacteriostatic preservative, which allows a reconstituted vial to be drawn from more than once during a research protocol.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eComposition:\u003c\/strong\u003e Water, benzyl alcohol 0.9% (9 mg\/mL). CAS 7732-18-5 (water), CAS 100-51-6 (benzyl alcohol). Specification per batch record.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at 20-25°C. \u003cstrong\u003eDo not freeze.\u003c\/strong\u003e Keep the vial closed and protect from light.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eResearch use only.\u003c\/strong\u003e Not for human consumption, veterinary use, or medical applications. This product is not a drug and is not offered for any therapeutic purpose.\u003c\/p\u003e","published_at":"2026-08-11T09:22:38-07:00","created_at":"2026-08-11T08:35:26-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Accessories","tags":["10mL Vial","Accessories","Made in the USA","Multi-Dose Vial"],"variants":[{"id":44138939646039,"title":"10mL","option1":"10mL","option2":null,"option3":null,"sku":"USPL-BACWATER-10ML","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"10.00","grams":0,"compare_at_price":null,"position":1,"product_id":7729560387671,"created_at":"2026-08-11T08:35:26-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882990960727,"created_at":"2026-08-17T12:22:54-07:00","position":1,"updated_at":"2026-08-17T12:22:56-07:00","product_id":7729560387671,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-bacteriostatic-water-10ml_a80bdf39-5b1e-41b5-8527-6a4b17959f80.png?v=1786994576","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mL"]}]},{"id":7712861323351,"title":"PT-141 Oral Spray","handle":"pt-141-oral-spray","body_html":"\u003ch3\u003ePT-141 (Bremelanotide) — oral format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized PT-141 (Bremelanotide) vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003emelanocortin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.\u003c\/p\u003e\u003cp\u003eBremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003ePT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin signaling\u003c\/li\u003e\n\u003cli\u003eMC4R neurobiology\u003c\/li\u003e\n\u003cli\u003esexual arousal pharmacodynamics\u003c\/li\u003e\n\u003cli\u003eCNS peptide signaling\u003c\/li\u003e\n\u003cli\u003epeptide pharmacokinetics\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle study administration\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous PT-141 clinical pharmacology study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle crossover study administration\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eIntranasal PT-141 plus sildenafil study in men with erectile dysfunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003eas labeled for the approved product\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eFDA-approved bremelanotide product label context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003ePT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003ebremelanotide, PT-141, melanocortin receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eBremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for PT-141\u003c\/strong\u003e\u003cbr\u003ePublished PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for PT-141\u003c\/strong\u003e\u003cbr\u003eReconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage per day\u003c\/strong\u003e\u003cbr\u003ePT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does PT-141 take\u003c\/strong\u003e\u003cbr\u003eClinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 half life\u003c\/strong\u003e\u003cbr\u003eBremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan PT-141 be stacked\u003c\/strong\u003e\u003cbr\u003eIt has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16839319\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15833522\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:08:02-07:00","created_at":"2026-07-27T01:07:15-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["oral","research-use-only"],"variants":[{"id":44076492324951,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-PT-141-ORAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861323351,"created_at":"2026-07-27T01:07:15-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35722611228759,"created_at":"2026-08-01T14:57:06-07:00","position":1,"updated_at":"2026-08-01T14:57:08-07:00","product_id":7712861323351,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-pt-141-10mg.png?v=1785621428","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712861290583,"title":"Oxytocin Oral Spray","handle":"oxytocin-oral-spray","body_html":"\u003ch3\u003eOxytocin — oral format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Oxytocin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eEndogenous nonapeptide hormone\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eOxytocin is an endogenous nonapeptide synthesized in the hypothalamus and released by the posterior pituitary. It is among the most thoroughly characterized peptides in human medicine because of long-standing obstetric uses, while a parallel research literature explores social cognition, stress responsivity, metabolic signals, and pain processing.\u003c\/p\u003e\u003cp\u003ePharmacologically, oxytocin is notable for a very short plasma half-life after intravenous dosing, which is why obstetric protocols often rely on controlled infusions. Research outside obstetrics frequently uses intranasal delivery when central nervous system questions are in view; subcutaneous routes appear in selected experimental pain and animal studies. A 2024 randomized trial reported that a low microgram-range subcutaneous dose modulated heat-pain ratings in healthy adults, adding a peer-reviewed SC data point.\u003c\/p\u003e\u003cp\u003eEducational dosage content must separate approved obstetric regimens, intranasal social-neuroscience doses (often 24 IU in experimental paradigms), and research-peptide vial math. This page is research-and-education oriented with research-use-only framing for non-labeled contexts—not a guide for unsupervised hormone use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eOxytocin binds the G protein-coupled oxytocin receptor (OXTR), expressed in uterus, mammary tissue, brain circuits, and peripheral sites. Receptor activation engages phospholipase C and calcium-dependent pathways that drive uterine smooth-muscle contraction and milk ejection in physiologic contexts. Centrally, OXTR signaling modulates social salience, anxiety-related circuits, and autonomic tone in experimental paradigms. Peripheral analgesic effects discussed in recent SC research may involve local receptor mechanisms in addition to any central actions.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobstetric pharmacology\u003c\/li\u003e\n\u003cli\u003esocial neuroscience\u003c\/li\u003e\n\u003cli\u003estress and affiliation biology\u003c\/li\u003e\n\u003cli\u003eexperimental pain modulation\u003c\/li\u003e\n\u003cli\u003emetabolic and autonomic research\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eObstetric clinical pharmacologists, affective and social neuroscientists, pain researchers, and endocrinology labs mapping OXTR distribution all work with oxytocin. Behavioral science groups dominate the intranasal literature. Peptide-education audiences often arrive via research-vial contexts and need help distinguishing IU obstetric dosing from mcg research vials.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e4 mcg\u003c\/td\u003e\n\u003ctd\u003esingle-dose experimental\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eExperimental subcutaneous research (example peer-reviewed human SC study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003estudy-defined (often single or limited repeated sessions)\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommon intranasal experimental neuroscience paradigms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10 mcg – 100 mcg\u003c\/td\u003e\n\u003ctd\u003evaries widely in informal sources\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSecondary research-peptide discussions of SC ranges (less standardized than obstetric IV\/IM labeling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eProtect from heat and light; refrigerated storage is standard for oxytocin preparations. Reconstituted research solutions should be kept cold, tightly capped, and discarded per stability guidance. Oxytocin is oxidation- and temperature-sensitive relative to hardier lyophilized research peptides.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNeuroscience studies typically administer oxytocin alone when measuring social or stress endpoints. Combining with other neuropeptides confounds interpretation of OXTR-specific effects. Obstetric clinical protocols likewise do not stack research peptides; they follow labeled labor or postpartum pathways under medical supervision.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eOXT, OT, alpha-hypophamine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eAbout 1-6 minutes plasma half-life after IV administration commonly cited; effective central effects after intranasal dosing are discussed on longer behavioral timescales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for oxytocin peptide?\u003c\/strong\u003e\u003cbr\u003eIt depends entirely on context. Obstetric labeling uses IU for IV infusion or IM injection under clinical care. Social neuroscience often studies about 24 IU intranasally. A 2024 pain trial used 4 mcg subcutaneously as a single experimental dose. Research-vial mcg charts are not interchangeable with labor-and-delivery orders.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for oxytocin?\u003c\/strong\u003e\u003cbr\u003eFor a 10 mg research vial, even 2-3 mL produces a very concentrated solution relative to low-mcg experimental targets, so serial dilution may be required for accurate microgram dosing. Document every dilution step. Clinical products arrive with their own diluents and concentrations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage per day\u003c\/strong\u003e\u003cbr\u003eThere is no general per-day research standard analogous to once-weekly incretins. Obstetric use is continuous or event-driven. Behavioral studies are usually session-based. Chronic daily SC schedules online should be treated skeptically without primary support.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage chart\u003c\/strong\u003e\u003cbr\u003eSeparate charts by route: IU for labeled obstetric products, IU for intranasal experimental sprays, and mcg for reconstituted research vials. Include the conversion note that product-specific IU-mcg relationships must be confirmed on the label.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does oxytocin take?\u003c\/strong\u003e\u003cbr\u003eIV obstetric effects on uterine tone can appear within minutes. Intranasal behavioral tasks are often timed 30-45 minutes after dosing in experimental protocols. SC analgesic endpoints in the 2024 trial were assessed in the post-injection experimental window defined by that study.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of oxytocin?\u003c\/strong\u003e\u003cbr\u003ePlasma half-life after IV dosing is commonly summarized around 1-6 minutes (sometimes cited near 3-5 minutes), which is why infusions are used clinically. Intranasal and SC kinetics differ; central behavioral effects are not identical to plasma half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan oxytocin be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eControlled research almost always isolates oxytocin when OXTR questions matter. Stacking with other neuroendocrine peptides muddies receptor-level inference. Clinical obstetric care follows dedicated protocols, not peptide stacks.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is oxytocin dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003eConvert vial mg to mcg (1 mg = 1,000 mcg), divide by diluent mL to get mcg\/mL, then multiply by mL drawn. Because target experimental mcg amounts can be tiny, use adequate dilution and a precision syringe. Cross-check with a dosage calculator and a second person when preparing research aliquots.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38642595\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSubcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8568623\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eBioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31286109\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLong-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:08:01-07:00","created_at":"2026-07-27T01:07:11-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["oral","research-use-only"],"variants":[{"id":44076492292183,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-OXYTOCIN-ORAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861290583,"created_at":"2026-07-27T01:07:11-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35722611163223,"created_at":"2026-08-01T14:57:02-07:00","position":1,"updated_at":"2026-08-01T14:57:03-07:00","product_id":7712861290583,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-oxytocin-10mg.png?v=1785621423","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712861257815,"title":"GLP-2T Oral Spray","handle":"glp-2t-oral-spray","body_html":"\u003ch3\u003eGLP-2T — oral format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-2T vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003edual incretin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is a long-acting peptide engineered to activate both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Large clinical trials have studied once-weekly GLP-2T in metabolic endpoints including glycemic measures, body weight, cardiometabolic markers, and comparative incretin pharmacology.\u003c\/p\u003e\u003cp\u003eGLP-2T has FDA-approved counterparts, including Mounjaro and Zepbound, for their specific approved uses and labeled formulations. Research-grade GLP-2T powder is not Mounjaro or Zepbound, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published trial dose arms or approved-product contexts, not recommendations.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-2T activates GIP and GLP-1 receptors, linking two incretin pathways that influence insulin secretion, glucagon dynamics, gastric emptying, appetite-related signaling, and energy-balance endpoints. Its fatty-acid modification supports prolonged albumin binding and once-weekly exposure in approved-product studies. Research comparisons often evaluate whether dual incretin signaling produces different metabolic and tolerability profiles than selective GLP-1 receptor agonism.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eincretin biology\u003c\/li\u003e\n\u003cli\u003eGIP receptor signaling\u003c\/li\u003e\n\u003cli\u003eGLP-1 receptor signaling\u003c\/li\u003e\n\u003cli\u003emetabolic pharmacology\u003c\/li\u003e\n\u003cli\u003ebody weight and glycemic endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is studied by endocrinologists, obesity researchers, cardiometabolic trialists, pharmacokinetic modelers, and regulatory scientists. Quality and formulation specialists distinguish regulated finished products from research-grade materials because they are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURPASS clinical trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURMOUNT obesity trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eApproved GLP-2T products have label-specific refrigerated storage instructions; research-grade lyophilized material is typically stored frozen or refrigerated per supplier specifications and protected from moisture and light.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eGLP-2T is often compared with GLP-1 receptor agonists, but combining incretin compounds or layering metabolic agents can confound appetite, glucose, gastrointestinal, and body-weight endpoints. Research-grade GLP-2T should never be positioned as a substitute for Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3298176, dual GIP\/GLP-1 receptor agonist, GIP\/GLP-1 agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eApproximately 5 days is commonly cited for GLP-2T in clinical pharmacology and labeling contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for GLP-2T\u003c\/strong\u003e\u003cbr\u003ePublished trials commonly studied 5, 10, and 15 mg once weekly dose arms. Those data describe clinical trial or approved-product contexts, not research-grade material use.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for GLP-2T\u003c\/strong\u003e\u003cbr\u003eResearch reconstitution volumes often use 1-3 mL depending on vial strength and target concentration. This is concentration math only.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage per day\u003c\/strong\u003e\u003cbr\u003eThe major clinical literature uses once-weekly exposure, not daily dosing. Research-grade GLP-2T is RUO and not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should distinguish trial dose arms, approved product titration, and lab concentration examples. These should not be blended.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does GLP-2T take\u003c\/strong\u003e\u003cbr\u003eTrials evaluate metabolic endpoints over weeks to months, while pharmacokinetic steady state depends on its multi-day half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T half life\u003c\/strong\u003e\u003cbr\u003eGLP-2T is commonly cited with an approximate 5-day half-life, supporting once-weekly dosing in approved-product studies.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan GLP-2T be stacked\u003c\/strong\u003e\u003cbr\u003eCombination metabolic research requires careful controls and medical-regulatory distinction. RUO GLP-2T is not Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T versus GLP-1 S Once Weekly in Patients with Type 2 Diabetes.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T Once Weekly for the Treatment of Obesity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35133415\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of Subcutaneous GLP-2T vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:59-07:00","created_at":"2026-07-27T01:07:06-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["oral","research-use-only"],"variants":[{"id":44076492259415,"title":"20mg","option1":"20mg","option2":null,"option3":null,"sku":"USPL-GLP-2T-ORAL-SPRAY-20MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247770628183,"product_id":7712861257815,"position":1,"created_at":"2026-09-23T14:23:03-07:00","updated_at":"2026-09-23T14:23:05-07:00","alt":"GLP-2T Oral Spray 20mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-oral-20mg.png?v=1790198585","variant_ids":[44076492259415]},"available":true,"price":"145.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861257815,"created_at":"2026-07-27T01:07:07-07:00","updated_at":"2026-09-23T23:45:45-07:00"},{"id":44308349747287,"title":"40mg","option1":"40mg","option2":null,"option3":null,"sku":null,"requires_shipping":true,"taxable":true,"featured_image":{"id":36247770824791,"product_id":7712861257815,"position":2,"created_at":"2026-09-23T14:23:07-07:00","updated_at":"2026-09-23T14:23:09-07:00","alt":"GLP-2T Oral Spray 40mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-oral-40mg.png?v=1790198589","variant_ids":[44308349747287]},"available":true,"price":"220.00","grams":0,"compare_at_price":null,"position":2,"product_id":7712861257815,"created_at":"2026-09-17T12:48:44-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":36247770628183,"created_at":"2026-09-23T14:23:03-07:00","position":1,"updated_at":"2026-09-23T14:23:05-07:00","product_id":7712861257815,"variant_ids":[44076492259415],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-oral-20mg.png?v=1790198585","width":1254,"height":1254},{"id":36247770824791,"created_at":"2026-09-23T14:23:07-07:00","position":2,"updated_at":"2026-09-23T14:23:09-07:00","product_id":7712861257815,"variant_ids":[44308349747287],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-oral-40mg.png?v=1790198589","width":1254,"height":1254}],"options":[{"name":"Size","position":1,"values":["20mg","40mg"]}]},{"id":7712861225047,"title":"CJC-1295 \/ Ipamorelin Nasal Spray","handle":"cjc-1295-ipamorelin-nasal-spray","body_html":"\u003ch3\u003eCJC-1295, Ipamorelin — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized CJC-1295, Ipamorelin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003eCJC-1295 \/ Ipamorelin Nasal Spray combines CJC-1295 and Ipamorelin. Each component is summarised below as it appears in the published literature.\u003c\/p\u003e\u003ch4\u003eCJC-1295\u003c\/h4\u003e\u003cp\u003e\u003cem\u003eLong-acting GHRH analog\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to extend stimulation of pituitary GH release relative to native GHRH(1-29). The best-known research form includes a Drug Affinity Complex (DAC) moiety that enables covalent albumin binding after injection, markedly prolonging half-life and supporting multi-day GH\/IGF-1 elevations in published human pharmacokinetic studies.\u003c\/p\u003e\u003cp\u003eInvestigators value CJC-1295 as a tool compound for GH-axis pharmacology: it helped demonstrate that prolonged GHRH-receptor stimulation can raise GH and IGF-1 while still preserving pulsatile GH patterns in healthy adults. A shorter-acting related sequence (often discussed as CJC-1295 without DAC \/ Mod GRF 1-29) is used when labs want brief pulses instead of multi-day exposure.\u003c\/p\u003e\u003cp\u003eResearch-grade CJC-1295 is Research Use Only. It is not FDA-approved for human use and is not for human consumption. Reported ranges differ sharply between DAC and non-DAC forms; the figures below are literature references, not recommendations.\u003c\/p\u003e\u003ch4\u003eIpamorelin\u003c\/h4\u003e\u003cp\u003e\u003cem\u003eGrowth hormone secretagogue (ghrelin receptor agonist)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eIpamorelin is a pentapeptide growth hormone secretagogue that stimulates the ghrelin receptor (GHS-R1a). Researchers value it because early work suggested strong GH release with comparatively little stimulation of ACTH and cortisol at doses that still moved GH—an important selectivity contrast versus older GHRP scaffolds.\u003c\/p\u003e\u003cp\u003eHuman pharmacokinetic-pharmacodynamic modeling and multiple preclinical growth studies established the core profile: a short circulating half-life, a discrete GH pulse, and dose-responsive somatotropic signaling. Ipamorelin remains a frequent reference compound in GH-axis, body-composition, and secretagogue-combination research.\u003c\/p\u003e\u003cp\u003eIn research-supply contexts it is almost always handled as a lyophilized peptide for subcutaneous investigation. Content on this page is educational and research-use-only; ipamorelin is not an FDA-approved therapeutic product.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003ch4\u003eCJC-1295\u003c\/h4\u003e\u003cp\u003eCJC-1295 acts at the GHRH receptor on anterior-pituitary somatotrophs. Receptor activation increases cAMP and triggers GH secretion. In the DAC-bearing form, reactive conjugation to circulating albumin slows clearance, producing sustained GHRH-receptor tone. Downstream, elevated GH drives hepatic and local IGF-1 production. Studies report that physiologic GH pulsatility can persist even under continuous analog stimulation.\u003c\/p\u003e\u003ch4\u003eIpamorelin\u003c\/h4\u003e\u003cp\u003eIpamorelin binds the growth hormone secretagogue receptor GHS-R1a, the same receptor activated by ghrelin. Receptor activation on pituitary somatotrophs promotes GH vesicle release. Because the peptide is relatively selective, experimental comparisons often highlight GH elevation with muted collateral HPA-axis activation versus earlier GHRPs. The short half-life produces a pulse-like GH exposure rather than a flat, prolonged elevation.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGH\/IGF-1 axis pharmacology\u003c\/li\u003e\n\u003cli\u003elong-acting GHRH analog design\u003c\/li\u003e\n\u003cli\u003epituitary somatotroph signaling\u003c\/li\u003e\n\u003cli\u003ebody-composition biomarker research\u003c\/li\u003e\n\u003cli\u003ealbumin-bioconjugate peptide PK\u003c\/li\u003e\n\u003cli\u003egrowth hormone axis research\u003c\/li\u003e\n\u003cli\u003eghrelin receptor pharmacology\u003c\/li\u003e\n\u003cli\u003ebody composition and recovery models\u003c\/li\u003e\n\u003cli\u003ebone growth preclinical research\u003c\/li\u003e\n\u003cli\u003esecretagogue combination studies\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEndocrine pharmacologists, peptide-engineering groups, and GH-axis biology labs are the main audience. Anti-doping analytics groups have also published detection methods because GHRH analogs appear on prohibited-substance lists in sport contexts.\u003c\/p\u003e\u003cp\u003eEndocrinology labs, sports-medicine research groups, and peptide pharmacology teams use ipamorelin when they need a selective GH secretagogue comparator. It also appears in protocol papers exploring GHRH-analogue plus GHRP co-administration. The audience is research personnel, not patients seeking treatment advice.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCJC-1295\u003c\/td\u003e\n\u003ctd\u003e2 mg – 4.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle dose or multi-dose weekly-style cohorts\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eTeichman et al. healthy-adult study of CJC-1295 with DAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCJC-1295\u003c\/td\u003e\n\u003ctd\u003e100 mcg – 300 mcg\u003c\/td\u003e\n\u003ctd\u003eone to three times daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eCommonly cited research-protocol ranges for non-DAC \/ Mod GRF 1-29 style analogs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIpamorelin\u003c\/td\u003e\n\u003ctd\u003e200 mcg – 300 mcg\u003c\/td\u003e\n\u003ctd\u003e1–3 times daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eCommonly cited in research and laboratory protocol discussions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIpamorelin\u003c\/td\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle \/ investigational infusion\u003c\/td\u003e\n\u003ctd\u003eintravenous\u003c\/td\u003e\n\u003ctd\u003eHuman IV PK\/PD dose-escalation study (Gobburu et al.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003ch4\u003eCJC-1295\u003c\/h4\u003e\u003cp\u003eStore lyophilized peptide refrigerated or frozen, away from light and humidity. After reconstitution, refrigerate and aliquot if the protocol requires repeated sampling over multiple days.\u003c\/p\u003e\u003ch4\u003eIpamorelin\u003c\/h4\u003e\u003cp\u003eKeep lyophilized vials cold, dry, and protected from light. After reconstitution with bacteriostatic water, refrigerate and avoid repeated warm-cold cycling; many labs aliquot to limit handling stress.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003ch4\u003eCJC-1295\u003c\/h4\u003e\u003cp\u003eResearch protocols frequently examine CJC-1295 together with a ghrelin-mimetic GHRP or GHS-R agonist such as ipamorelin or hexarelin because GHRH and ghrelin pathways can converge on GH release through complementary receptors. DAC versus non-DAC choice is usually the first experimental branch point.\u003c\/p\u003e\u003ch4\u003eIpamorelin\u003c\/h4\u003e\u003cp\u003eIpamorelin is frequently discussed alongside GHRH analogues such as CJC-1295 (with or without DAC) or sermorelin because the two classes hit complementary nodes of GH release. Research stacks aim to amplify pulse amplitude while preserving physiologic timing. Literature comparisons sometimes include other GHRPs (GHRP-2, GHRP-6) when ranking selectivity and side-effect profiles.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eCJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, Modified GRF 1-29 related analog, NNC 26-0161, growth hormone releasing peptide ipamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eCJC-1295: ~5.8-8.1 days reported for CJC-1295 with DAC; ~30 minutes class range for non-DAC GRF analogs — Ipamorelin: ~2 hours terminal half-life (reported in human IV PK modeling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eCJC-1295: What is CJC-1295 peptide dosage in published research?\u003c\/strong\u003e\u003cbr\u003eFor CJC-1295 with DAC, Teichman et al. studied about 30-60 mcg\/kg subcutaneously in healthy adults. Non-DAC analogs are commonly discussed around 100-300 mcg per exposure because they clear much faster.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIpamorelin: What is the dosage for ipamorelin?\u003c\/strong\u003e\u003cbr\u003eLaboratory and secondary research summaries most often cite roughly 200–300 mcg per subcutaneous administration, sometimes repeated up to two or three times daily because of the short half-life. Published human PK work used IV mcg\/kg infusions rather than a single universal SC chart.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCJC-1295: What is the difference between CJC-1295 with DAC and without DAC?\u003c\/strong\u003e\u003cbr\u003eDAC enables albumin binding and multi-day activity. Without DAC, the peptide behaves like a short-acting GHRH analog and is typically studied with more frequent administration.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIpamorelin: How much BAC water for ipamorelin?\u003c\/strong\u003e\u003cbr\u003eA practical research reconstitution is 2–3 mL bacteriostatic water in a 5 mg or 10 mg vial. Example: 5 mg + 2.5 mL yields 200 mcg per 10 units on a U-100 syringe. Confirm arithmetic against your exact vial label.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCJC-1295: Does CJC-1295 destroy normal GH pulses?\u003c\/strong\u003e\u003cbr\u003ePublished work reported that pulsatile GH secretion can persist during continuous stimulation by long-acting CJC-1295, with higher mean and trough GH levels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIpamorelin: Ipamorelin dosage per day?\u003c\/strong\u003e\u003cbr\u003eDaily totals in informal research discussions often land near 200–900 mcg\/day when split across one to three injections. Those figures are commonly cited reference ranges, not individualized medical directions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCJC-1295: Is CJC-1295 FDA-approved?\u003c\/strong\u003e\u003cbr\u003eNo. Research-grade CJC-1295 is RUO laboratory material and is not an approved drug product for human use.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIpamorelin: Ipamorelin dosage chart?\u003c\/strong\u003e\u003cbr\u003eCharts usually convert vial strength and diluent volume into mcg-per-tick-mark on an insulin syringe, then list once-, twice-, or thrice-daily pulse schedules. Use them only as research math aids.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003ePulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15817669\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eHuman growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16822960\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19386527\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eActivation of the GH\/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eIpamorelin, the first selective growth hormone secretagogue.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10496658\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003ePharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10373343\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:57-07:00","created_at":"2026-07-27T01:07:03-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076492226647,"title":"10mg\/10mg","option1":"10mg\/10mg","option2":null,"option3":null,"sku":"USPL-CJC-1295-IPAMORELIN-NASAL-SPRAY-10MG-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"188.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861225047,"created_at":"2026-07-27T01:07:03-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717385650263,"created_at":"2026-08-01T00:33:09-07:00","position":1,"updated_at":"2026-08-01T00:33:10-07:00","product_id":7712861225047,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-cjc-1295-ipamorelin-10mg-10mg_d1cc4ac9-198b-403e-ad12-a03138970156.png?v=1785569590","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg\/10mg"]}]},{"id":7712861192279,"title":"Semax Nasal Spray","handle":"semax-nasal-spray","body_html":"\u003ch3\u003eSemax — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Semax vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eSynthetic ACTH(4-10) heptapeptide nootropic \/ neuroprotective research peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSemax is a synthetic heptapeptide analogue of ACTH(4-10) with a Pro-Gly-Pro extension that improves stability relative to the native fragment. It has a long research history in Russian neuroscience for nootropic, neuroprotective, and cerebrovascular questions, with intranasal delivery as the dominant route.\u003c\/p\u003e\u003cp\u003eIndexed studies examine brain penetration after nasal dosing, membrane binding and biodegradation, BDNF-related signaling, and clinical-research use in acute ischemic stroke settings where multi-milligram daily intranasal totals were tested. Western large-scale replication is more limited than the domestic literature base.\u003c\/p\u003e\u003cp\u003eFor dosage education, distinguish animal mcg\/kg work, human stroke-trial milligram schedules, and lower-microgram nootropic research-chemical practices discussed online. Only documented literature ranges are emphasized here, under research-use-only framing.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eSemax does not act like a classical long-acting endocrine ACTH drug at therapeutic glucocorticoid doses. Research points to rapid CNS availability after intranasal dosing, specific binding interactions, proteolytic processing to shorter fragments, and downstream effects on neurotrophic systems including BDNF protein levels in animal work. Functional effects can outlast intact peptide concentrations because of gene-expression and network-level changes.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003enootropic and cognitive neuroscience\u003c\/li\u003e\n\u003cli\u003eischemic stroke recovery research\u003c\/li\u003e\n\u003cli\u003eBDNF and neurotrophic signaling\u003c\/li\u003e\n\u003cli\u003eintranasal peptide delivery\u003c\/li\u003e\n\u003cli\u003eACTH fragment structure-activity studies\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNeuropharmacology labs, stroke-research clinicians in regions where Semax was developed, and blood-brain-barrier delivery groups are the primary audiences. Cognitive-enhancement communities drive search traffic, but legitimate content should stay anchored to peer-reviewed neuroscience rather than lifestyle dosing culture.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e12 mg – 18 mg\u003c\/td\u003e\n\u003ctd\u003edaily totals over 5–10 days\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eHuman acute ischemic stroke clinical research (intranasal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e200 mcg – 600 mcg\u003c\/td\u003e\n\u003ctd\u003e1–2 times daily\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommonly cited nootropic research-chemical discussions (not equivalent to stroke-trial dosing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized Semax is stored refrigerated or frozen, dry and dark. Reconstituted nasal research solutions are kept cold; sterile technique matters because the route is mucosal.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eResearch comparisons often place Semax beside Selank (another Russian regulatory peptide) when mapping anxiolytic vs nootropic peptide tools. Stroke papers evaluate it as an add-on to standard care rather than as part of a multi-peptide lifestyle stack. BDNF-pathway discussions sometimes reference other neurotrophic strategies at the mechanistic level only.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eMet-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) analogue, MEHFPGP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eRapid systemic degradation (minutes-scale peptide clearance reported); functional effects may last many hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for Semax?\u003c\/strong\u003e\u003cbr\u003eIt depends which literature you mean. Acute stroke research used roughly 12–18 mg\/day intranasally for several days. Secondary nootropic research discussions often cite a few hundred micrograms intranasally. Do not collapse those into one chart without labels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much BAC water for Semax?\u003c\/strong\u003e\u003cbr\u003eFor lyophilized powder, researchers pick a diluent volume that matches nasal spray or drop calibration—commonly 2–3 mL per multi-milligram vial. Some finished research preparations arrive already in solution.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax dosage per day?\u003c\/strong\u003e\u003cbr\u003eStroke-trial daily totals were in the low multi-milligram range. Cognitive research-chemical practice often discusses split intranasal mcg doses once or twice daily. Route in both cases is typically nasal, not subcutaneous.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax dosage chart?\u003c\/strong\u003e\u003cbr\u003eA careful chart separates (1) animal mcg\/kg data, (2) human stroke mg\/day protocols, and (3) lower mcg secondary references. Mixing them without context creates false precision.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is Semax half life?\u003c\/strong\u003e\u003cbr\u003eThe intact peptide is degraded quickly, yet behavioral or physiologic readouts in animal work can persist far longer, consistent with downstream neurotrophic signaling rather than continuous high plasma levels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan Semax be stacked?\u003c\/strong\u003e\u003cbr\u003eResearch discourse sometimes pairs it conceptually with Selank or standard stroke therapy. Controlled evidence for elaborate multi-peptide stacks is limited; combinations remain experimental.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs Semax injected or nasal?\u003c\/strong\u003e\u003cbr\u003eThe dominant researched human route is intranasal. That is a major practical difference from most injectable research peptides on dosage pages.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs Semax an approved drug everywhere?\u003c\/strong\u003e\u003cbr\u003eIt has an established research\/clinical history in Russia and related literature. It is not broadly approved as a consumer nootropic in the United States; treat U.S. context as research-use education.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11517472\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16635254\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSemax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16523722\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9173745\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:56-07:00","created_at":"2026-07-27T01:06:59-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076492193879,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-SEMAX-NASAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"120.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861192279,"created_at":"2026-07-27T01:06:59-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717385388119,"created_at":"2026-08-01T00:33:00-07:00","position":1,"updated_at":"2026-08-01T00:33:02-07:00","product_id":7712861192279,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-semax-10mg_ae190acb-fde3-4b05-99b8-d4d080537dd7.png?v=1785569582","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712861159511,"title":"Selank Nasal Spray","handle":"selank-nasal-spray","body_html":"\u003ch3\u003eSelank — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Selank vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003esynthetic heptapeptide anxiolytic research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSelank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro sequence. Research has examined anxiolytic-like behavior, cognitive endpoints, cytokine signaling, monoamine systems, and gene-expression changes related to GABAergic neurotransmission. Much of the literature comes from Russian research groups and includes both clinical and preclinical designs.\u003c\/p\u003e\u003cp\u003eEducation content should keep Selank in research-use framing. It is not an FDA-approved drug product, and research-grade Selank is Research Use Only and not for human consumption. Reported ranges below reflect published human or animal study contexts where available and should not be treated as a protocol.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eSelank is studied as a tuftsin analog with neuroimmune and neuromodulatory effects. Published work links it to GABAergic gene-expression changes, monoamine metabolism, cytokine modulation, and anxiolytic-like behavioral outcomes. Unlike a single-receptor sedative model, Selank appears in the literature as a multi-pathway peptide with immune and CNS dimensions. That makes endpoint selection and comparator choice important in research design.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eanxiety-model behavior\u003c\/li\u003e\n\u003cli\u003eGABAergic signaling\u003c\/li\u003e\n\u003cli\u003eneuroimmune modulation\u003c\/li\u003e\n\u003cli\u003ecognitive research\u003c\/li\u003e\n\u003cli\u003ecytokine response\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSelank is studied by neuropharmacologists, behavioral neuroscience groups, psychopharmacology researchers, and immunology-focused peptide labs. Translational reviewers pay close attention to country of origin, formulation, route, and trial design.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mcg – 2.7 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eClinical intranasal Selank literature commonly discusses sub-milligram to milligram daily exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e100 mcg – 300 mcg\u003c\/td\u003e\n\u003ctd\u003edaily course in animal protocols\u003c\/td\u003e\n\u003ctd\u003eintraperitoneal or intranasal in animal studies\u003c\/td\u003e\n\u003ctd\u003eRat behavioral research with Selank\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized Selank is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and handled aseptically.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eSelank is often discussed with Semax, nootropic compounds, or anxiolytic comparators, but combined CNS protocols can obscure whether changes reflect peptide effects, stress adaptation, or comparator pharmacology. Research designs should define behavioral endpoints and avoid converting regional clinical literature into general dosing advice.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eThr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, tuftsin analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eNot firmly established in widely cited human pharmacokinetic literature; Selank is generally discussed as a short peptide with effects that may outlast measurable exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for Selank\u003c\/strong\u003e\u003cbr\u003ePublished Selank discussions include intranasal human study contexts and animal mcg\/kg work. These are reference values only, not recommendations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for Selank\u003c\/strong\u003e\u003cbr\u003eSmall research vials are often modeled with 1-2 mL reconstitution volumes. The chosen volume sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily exposure in the literature depends on route, formulation, and study design. Research-grade Selank is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank dosage chart\u003c\/strong\u003e\u003cbr\u003eA responsible chart should separate human intranasal study references from animal per-kg experiments and clearly label all values as research context.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does Selank take\u003c\/strong\u003e\u003cbr\u003eBehavioral and subjective endpoints in studies are usually assessed over days to weeks, while molecular endpoints can be measured on shorter timelines.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank half life\u003c\/strong\u003e\u003cbr\u003eA practical human half-life is not well standardized in the mainstream literature. Effects may be discussed separately from simple plasma persistence.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan Selank be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied with comparators such as anxiolytic drugs or other peptides, but stacking complicates attribution and is not a use recommendation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30255741\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003ePeptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25176261\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26924987\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:54-07:00","created_at":"2026-07-27T01:06:54-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076492161111,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-SELANK-NASAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"120.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861159511,"created_at":"2026-07-27T01:06:54-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717381455959,"created_at":"2026-08-01T00:32:52-07:00","position":1,"updated_at":"2026-08-01T00:32:54-07:00","product_id":7712861159511,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-selank-10mg_3cb12c56-96e0-4675-86c9-b6e5072c6081.png?v=1785569574","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712861093975,"title":"NAD+ Nasal Spray","handle":"nad-nasal-spray","body_html":"\u003ch3\u003eNAD+ — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized NAD+ vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eredox coenzyme and NAD biology research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is not a peptide; it is a nucleotide-derived coenzyme used in virtually every cell. Research interest centers on its role in redox reactions, mitochondrial metabolism, sirtuin signaling, PARP activity, and age-associated changes in cellular energy handling. Education pages often group NAD+ with peptide protocols because it is sold in similar lyophilized formats, but mechanistically it belongs to metabolism and coenzyme biology.\u003c\/p\u003e\u003cp\u003ePublished human work most often studies NAD+ precursors such as nicotinamide riboside or nicotinamide mononucleotide, while direct NAD+ material appears in more limited pharmacokinetic and infusion-oriented discussions. Any research-grade NAD+ powder is Research Use Only and is not the same thing as a regulated drug product. Reported ranges below are reference points from published precursor or NAD-related literature, not instructions for use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eNAD+ cycles between oxidized and reduced forms to shuttle electrons through glycolysis, the TCA cycle, and oxidative phosphorylation. It also serves as a substrate for enzymes including sirtuins, PARPs, CD38, and other NAD-consuming systems. When NAD+ availability changes, downstream effects can include altered mitochondrial respiration, DNA damage signaling, inflammatory tone, and cellular stress responses. Researchers study both direct NAD+ and precursor strategies because cells tightly regulate NAD synthesis, salvage, and consumption.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emitochondrial function\u003c\/li\u003e\n\u003cli\u003eaging biology\u003c\/li\u003e\n\u003cli\u003eredox metabolism\u003c\/li\u003e\n\u003cli\u003ecellular stress response\u003c\/li\u003e\n\u003cli\u003eNAD precursor pharmacology\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is studied by mitochondrial biologists, aging researchers, nutrition scientists, and pharmacologists. Clinical investigators more commonly study oral NAD+ precursors, while analytical labs examine NAD+ handling, stability, and compartment-specific measurement.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mg – 1000 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eHuman oral nicotinamide riboside studies commonly cited in NAD+ precursor literature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mg\u003c\/td\u003e\n\u003ctd\u003esingle study dose\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eAcute human cerebral NAD+ measurement study using nicotinamide riboside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized NAD+ is commonly stored frozen and protected from moisture and light; reconstituted material is typically kept refrigerated and used promptly in laboratory settings.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNAD+ is often discussed beside mitochondrial and recovery-focused compounds, but the strongest literature is on NAD metabolism rather than peptide stacking. Researchers usually separate NAD+ or precursor variables from other interventions so changes in redox markers, methylation demand, and mitochondrial readouts can be interpreted cleanly.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003enicotinamide adenine dinucleotide, oxidized NAD, NAD plus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eContext-dependent; circulating NAD+ and precursors are rapidly metabolized, while downstream NAD pool changes may last longer than plasma exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for NAD+\u003c\/strong\u003e\u003cbr\u003eFor education only: published human studies most often report oral NAD+ precursor amounts, commonly in the hundreds of milligrams to 1 gram daily. That is not a recommendation and is not the same as dosing research-grade NAD+.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for NAD+\u003c\/strong\u003e\u003cbr\u003eResearch suppliers commonly discuss 5-20 mL reconstitution volumes for larger NAD+ vials, depending on target concentration. Reconstitution math is a lab calculation, not a human-use instruction.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily values in the literature usually refer to oral precursors such as nicotinamide riboside. Direct NAD+ protocols vary by research model and should be read from the original paper.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage chart\u003c\/strong\u003e\u003cbr\u003eA useful chart should separate precursor studies, direct NAD+ analytical work, route, concentration, and species. Combining them into one dosing chart can be misleading.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does NAD+ take\u003c\/strong\u003e\u003cbr\u003eSome precursor studies measure NAD-related metabolites within hours, while tissue or functional endpoints are usually assessed over weeks. Timing depends on the assay and model.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ half life\u003c\/strong\u003e\u003cbr\u003eThere is no single practical half-life for all NAD+ research because NAD+ is rapidly turned over and compartmentalized. Researchers often track metabolite pools rather than plasma half-life alone.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan NAD+ be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied alongside other compounds, but clean protocols isolate variables. Research-use-only material should not be treated as a wellness stack or drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37068054\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eDietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29599478\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39044608\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAcute nicotinamide riboside supplementation increases human cerebral NAD(+) levels in vivo.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:53-07:00","created_at":"2026-07-27T01:06:50-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076492062807,"title":"500mg","option1":"500mg","option2":null,"option3":null,"sku":"USPL-NAD-NASAL-SPRAY-500MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"125.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861093975,"created_at":"2026-07-27T01:06:50-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717375819863,"created_at":"2026-08-01T00:32:44-07:00","position":1,"updated_at":"2026-08-01T00:32:45-07:00","product_id":7712861093975,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-nadplus-500mg_a5c0ef9b-fd95-4113-84dd-fa3b058a9ee1.png?v=1785569565","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["500mg"]}]},{"id":7712861061207,"title":"PT-141 Nasal Spray","handle":"pt-141-nasal-spray","body_html":"\u003ch3\u003ePT-141 (Bremelanotide) — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized PT-141 (Bremelanotide) vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003emelanocortin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.\u003c\/p\u003e\u003cp\u003eBremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003ePT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin signaling\u003c\/li\u003e\n\u003cli\u003eMC4R neurobiology\u003c\/li\u003e\n\u003cli\u003esexual arousal pharmacodynamics\u003c\/li\u003e\n\u003cli\u003eCNS peptide signaling\u003c\/li\u003e\n\u003cli\u003epeptide pharmacokinetics\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle study administration\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous PT-141 clinical pharmacology study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle crossover study administration\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eIntranasal PT-141 plus sildenafil study in men with erectile dysfunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003eas labeled for the approved product\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eFDA-approved bremelanotide product label context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003ePT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003ebremelanotide, PT-141, melanocortin receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eBremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for PT-141\u003c\/strong\u003e\u003cbr\u003ePublished PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for PT-141\u003c\/strong\u003e\u003cbr\u003eReconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage per day\u003c\/strong\u003e\u003cbr\u003ePT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does PT-141 take\u003c\/strong\u003e\u003cbr\u003eClinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 half life\u003c\/strong\u003e\u003cbr\u003eBremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan PT-141 be stacked\u003c\/strong\u003e\u003cbr\u003eIt has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16839319\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15833522\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:51-07:00","created_at":"2026-07-27T01:06:46-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076492030039,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-PT-141-NASAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712861061207,"created_at":"2026-07-27T01:06:46-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717375787095,"created_at":"2026-08-01T00:32:36-07:00","position":1,"updated_at":"2026-08-01T00:32:37-07:00","product_id":7712861061207,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-pt-141-10mg_333a5d4f-b376-4aca-813a-0db7068bd163.png?v=1785569557","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712860995671,"title":"Oxytocin Nasal Spray","handle":"oxytocin-nasal-spray","body_html":"\u003ch3\u003eOxytocin — nasal spray format\u003c\/h3\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Oxytocin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eEndogenous nonapeptide hormone\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eOxytocin is an endogenous nonapeptide synthesized in the hypothalamus and released by the posterior pituitary. It is among the most thoroughly characterized peptides in human medicine because of long-standing obstetric uses, while a parallel research literature explores social cognition, stress responsivity, metabolic signals, and pain processing.\u003c\/p\u003e\u003cp\u003ePharmacologically, oxytocin is notable for a very short plasma half-life after intravenous dosing, which is why obstetric protocols often rely on controlled infusions. Research outside obstetrics frequently uses intranasal delivery when central nervous system questions are in view; subcutaneous routes appear in selected experimental pain and animal studies. A 2024 randomized trial reported that a low microgram-range subcutaneous dose modulated heat-pain ratings in healthy adults, adding a peer-reviewed SC data point.\u003c\/p\u003e\u003cp\u003eEducational dosage content must separate approved obstetric regimens, intranasal social-neuroscience doses (often 24 IU in experimental paradigms), and research-peptide vial math. This page is research-and-education oriented with research-use-only framing for non-labeled contexts—not a guide for unsupervised hormone use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eOxytocin binds the G protein-coupled oxytocin receptor (OXTR), expressed in uterus, mammary tissue, brain circuits, and peripheral sites. Receptor activation engages phospholipase C and calcium-dependent pathways that drive uterine smooth-muscle contraction and milk ejection in physiologic contexts. Centrally, OXTR signaling modulates social salience, anxiety-related circuits, and autonomic tone in experimental paradigms. Peripheral analgesic effects discussed in recent SC research may involve local receptor mechanisms in addition to any central actions.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobstetric pharmacology\u003c\/li\u003e\n\u003cli\u003esocial neuroscience\u003c\/li\u003e\n\u003cli\u003estress and affiliation biology\u003c\/li\u003e\n\u003cli\u003eexperimental pain modulation\u003c\/li\u003e\n\u003cli\u003emetabolic and autonomic research\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eObstetric clinical pharmacologists, affective and social neuroscientists, pain researchers, and endocrinology labs mapping OXTR distribution all work with oxytocin. Behavioral science groups dominate the intranasal literature. Peptide-education audiences often arrive via research-vial contexts and need help distinguishing IU obstetric dosing from mcg research vials.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e4 mcg\u003c\/td\u003e\n\u003ctd\u003esingle-dose experimental\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eExperimental subcutaneous research (example peer-reviewed human SC study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003estudy-defined (often single or limited repeated sessions)\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommon intranasal experimental neuroscience paradigms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10 mcg – 100 mcg\u003c\/td\u003e\n\u003ctd\u003evaries widely in informal sources\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSecondary research-peptide discussions of SC ranges (less standardized than obstetric IV\/IM labeling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eProtect from heat and light; refrigerated storage is standard for oxytocin preparations. Reconstituted research solutions should be kept cold, tightly capped, and discarded per stability guidance. Oxytocin is oxidation- and temperature-sensitive relative to hardier lyophilized research peptides.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNeuroscience studies typically administer oxytocin alone when measuring social or stress endpoints. Combining with other neuropeptides confounds interpretation of OXTR-specific effects. Obstetric clinical protocols likewise do not stack research peptides; they follow labeled labor or postpartum pathways under medical supervision.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eOXT, OT, alpha-hypophamine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eAbout 1-6 minutes plasma half-life after IV administration commonly cited; effective central effects after intranasal dosing are discussed on longer behavioral timescales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for oxytocin peptide?\u003c\/strong\u003e\u003cbr\u003eIt depends entirely on context. Obstetric labeling uses IU for IV infusion or IM injection under clinical care. Social neuroscience often studies about 24 IU intranasally. A 2024 pain trial used 4 mcg subcutaneously as a single experimental dose. Research-vial mcg charts are not interchangeable with labor-and-delivery orders.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for oxytocin?\u003c\/strong\u003e\u003cbr\u003eFor a 10 mg research vial, even 2-3 mL produces a very concentrated solution relative to low-mcg experimental targets, so serial dilution may be required for accurate microgram dosing. Document every dilution step. Clinical products arrive with their own diluents and concentrations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage per day\u003c\/strong\u003e\u003cbr\u003eThere is no general per-day research standard analogous to once-weekly incretins. Obstetric use is continuous or event-driven. Behavioral studies are usually session-based. Chronic daily SC schedules online should be treated skeptically without primary support.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin dosage chart\u003c\/strong\u003e\u003cbr\u003eSeparate charts by route: IU for labeled obstetric products, IU for intranasal experimental sprays, and mcg for reconstituted research vials. Include the conversion note that product-specific IU-mcg relationships must be confirmed on the label.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does oxytocin take?\u003c\/strong\u003e\u003cbr\u003eIV obstetric effects on uterine tone can appear within minutes. Intranasal behavioral tasks are often timed 30-45 minutes after dosing in experimental protocols. SC analgesic endpoints in the 2024 trial were assessed in the post-injection experimental window defined by that study.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of oxytocin?\u003c\/strong\u003e\u003cbr\u003ePlasma half-life after IV dosing is commonly summarized around 1-6 minutes (sometimes cited near 3-5 minutes), which is why infusions are used clinically. Intranasal and SC kinetics differ; central behavioral effects are not identical to plasma half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan oxytocin be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eControlled research almost always isolates oxytocin when OXTR questions matter. Stacking with other neuroendocrine peptides muddies receptor-level inference. Clinical obstetric care follows dedicated protocols, not peptide stacks.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is oxytocin dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003eConvert vial mg to mcg (1 mg = 1,000 mcg), divide by diluent mL to get mcg\/mL, then multiply by mL drawn. Because target experimental mcg amounts can be tiny, use adequate dilution and a precision syringe. Cross-check with a dosage calculator and a second person when preparing research aliquots.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38642595\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSubcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8568623\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eBioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31286109\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLong-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-27T01:07:50-07:00","created_at":"2026-07-27T01:06:42-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["nasal","research-use-only"],"variants":[{"id":44076491964503,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-OXYTOCIN-NASAL-SPRAY-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712860995671,"created_at":"2026-07-27T01:06:42-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717375688791,"created_at":"2026-08-01T00:32:27-07:00","position":1,"updated_at":"2026-08-01T00:32:29-07:00","product_id":7712860995671,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-oxytocin-10mg_43f67bfa-6959-439e-8867-e6e94beddf71.png?v=1785569549","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712860962903,"title":"IGF-1 LR3","handle":"igf-1-lr3","body_html":"\u003cp\u003eIGF-1 LR3 supplied as lyophilized powder in a 10 mL vial for laboratory research use only. Each lot is analyzed by an independent third-party laboratory; the lot-specific certificate of analysis is published on this page when available.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eThis product is not for human consumption.\u003c\/strong\u003e Not for diagnostic, therapeutic or veterinary use. Not FDA-approved. Keep out of reach of children.\u003c\/p\u003e","published_at":"2026-07-27T01:07:49-07:00","created_at":"2026-07-27T01:06:38-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["research-use-only","vial"],"variants":[{"id":44076491931735,"title":"1mg","option1":"1mg","option2":null,"option3":null,"sku":"USPL-IGF-1-LR3-1MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"140.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712860962903,"created_at":"2026-07-27T01:06:38-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882882662487,"created_at":"2026-08-17T11:47:09-07:00","position":1,"updated_at":"2026-08-17T11:47:11-07:00","product_id":7712860962903,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-igf-1-lr3-1mg.png?v=1786992431","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["1mg"]}]},{"id":7712860930135,"title":"VIP","handle":"vip","body_html":"\u003cp\u003eVIP supplied as lyophilized powder in a 10 mL vial for laboratory research use only. Each lot is analyzed by an independent third-party laboratory; the lot-specific certificate of analysis is published on this page when available.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eThis product is not for human consumption.\u003c\/strong\u003e Not for diagnostic, therapeutic or veterinary use. Not FDA-approved. Keep out of reach of children.\u003c\/p\u003e","published_at":"2026-07-27T01:07:47-07:00","created_at":"2026-07-27T01:06:33-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["research-use-only","vial"],"variants":[{"id":44076491898967,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-VIP-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"80.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712860930135,"created_at":"2026-07-27T01:06:33-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882881187927,"created_at":"2026-08-17T11:46:58-07:00","position":1,"updated_at":"2026-08-17T11:47:00-07:00","product_id":7712860930135,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-vip-10mg.png?v=1786992420","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["10mg"]}]},{"id":7712860897367,"title":"Kisspeptin","handle":"kisspeptin","body_html":"\u003cp\u003eKisspeptin supplied as lyophilized powder in a 10 mL vial for laboratory research use only. Each lot is analyzed by an independent third-party laboratory; the lot-specific certificate of analysis is published on this page when available.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eThis product is not for human consumption.\u003c\/strong\u003e Not for diagnostic, therapeutic or veterinary use. Not FDA-approved. Keep out of reach of children.\u003c\/p\u003e","published_at":"2026-07-27T01:07:46-07:00","created_at":"2026-07-27T01:06:28-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Research Peptide","tags":["research-use-only","vial"],"variants":[{"id":44076491866199,"title":"5mg","option1":"5mg","option2":null,"option3":null,"sku":"USPL-KISSPEPTIN-5MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"50.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712860897367,"created_at":"2026-07-27T01:06:28-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882880303191,"created_at":"2026-08-17T11:46:48-07:00","position":1,"updated_at":"2026-08-17T11:46:50-07:00","product_id":7712860897367,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-kisspeptin-5mg.png?v=1786992410","width":1600,"height":1600}],"options":[{"name":"Size","position":1,"values":["5mg"]}]},{"id":7712770687063,"title":"Tesamorelin Oral Spray","handle":"tesamorelin-oral","body_html":"\u003ch3\u003eTesamorelin — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Tesamorelin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eGrowth hormone-releasing hormone (GHRH) analog\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eTesamorelin is a stabilized analog of growth hormone-releasing hormone that stimulates pituitary GH secretion, raising IGF-1 and influencing body composition. It is distinctive among research-discussed peptides because a specific formulation received FDA approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.\u003c\/p\u003e\u003cp\u003ePhase 3 programs led by Falutz and colleagues demonstrated meaningful reductions in visceral adipose tissue over 26 weeks with daily subcutaneous administration, with extension data informing durability and metabolic secondary endpoints. Separate work evaluated liver fat and other cardiometabolic markers in HIV populations with central fat accumulation. These papers are the correct primary anchors for dosage education.\u003c\/p\u003e\u003cp\u003eOutside labeled use, tesamorelin appears in broader body-composition research conversations. Educational content should keep approved indication, trial doses, and off-label speculation clearly separated, and should use research-use-only language for non-labeled contexts. This page summarizes documented ranges for reference by research professionals.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eTesamorelin binds pituitary GHRH receptors, amplifying physiologic GH pulsatility rather than supplying exogenous growth hormone directly. Increased GH acts on hepatic and peripheral tissues to raise IGF-1, promote lipolysis in visceral fat depots, and support lean-mass signals. Preferential VAT reduction with relative subcutaneous fat sparing was a recurring theme in HIV lipodystrophy trials. Downstream metabolic effects on triglycerides and hepatic fat have been examined as secondary physiology.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eHIV-associated lipodystrophy\u003c\/li\u003e\n\u003cli\u003evisceral adiposity\u003c\/li\u003e\n\u003cli\u003eGH\/IGF-1 axis\u003c\/li\u003e\n\u003cli\u003ehepatic fat in endocrine research\u003c\/li\u003e\n\u003cli\u003ebody composition\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eInfectious-disease and endocrinology investigators working on HIV metabolic complications are the core clinical-research audience. Body-composition and NAFLD-oriented teams analyze VAT and liver-fat imaging endpoints. Peptide educators reference tesamorelin as a fully specified GHRH-analog case study with published phase 3 dose regimens.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2 mg\u003c\/td\u003e\n\u003ctd\u003eonce daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePivotal HIV lipodystrophy clinical trials (original 2 mg daily subcutaneous regimen)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 2 mg\u003c\/td\u003e\n\u003ctd\u003edaily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eResearch discussions of GH-axis body-composition protocols referencing the clinical dose anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eApproved product labeling specifies controlled storage and reconstitution steps; research lyophilizates should remain refrigerated per COA. Use diluent only as directed, refrigerate reconstituted solution, and discard after the labeled period.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eClinical trials evaluate tesamorelin on optimized antiretroviral and lifestyle backgrounds, not stacked with other GH secretagogues. Combining GHRH analogs with GHRPs\/ghrelin mimetics is sometimes hypothesized to amplify GH release but introduces confounding and safety-monitoring complexity. Research designs usually isolate the GHRH analog.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eTH9507, Egrifta, GHRH(1-44) analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort plasma half-life consistent with a GHRH-analog peptide; clinical effect is mediated via stimulated GH\/IGF-1 axis rather than continuous plasma presence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for tesamorelin?\u003c\/strong\u003e\u003cbr\u003ePivotal HIV-associated lipodystrophy trials used 2 mg subcutaneously once daily for the original formulation. That is the best-documented human dose anchor in the peer-reviewed literature. Newer branded presentations may list different nominal milligram strengths that are designed to be exposure-matched—always read the specific label or trial protocol.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for tesamorelin?\u003c\/strong\u003e\u003cbr\u003eFollow the product's reconstitution instructions when using approved kits. For research lyophilized vials, choose a diluent volume that delivers 2 mg in a convenient syringe volume (for example, 2 mg in 1 mL yields 2 mg\/mL). Do not assume multi-peptide blend volumes apply.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTesamorelin dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily dosing—not weekly—is the regimen used in the major VAT-reduction trials. Educational charts should show mcg or mg per day and note morning abdominal subcutaneous administration patterns described in clinical materials.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTesamorelin dosage chart\u003c\/strong\u003e\u003cbr\u003eA simple chart maps 2 mg daily to syringe units at your concentration. If reconstituted to 2 mg\/mL, 1.0 mL = 2 mg. IGF-1 monitoring schedules from clinical practice are separate from the injection-volume chart and belong in protocol documents.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does tesamorelin take?\u003c\/strong\u003e\u003cbr\u003ePrimary VAT imaging endpoints in phase 3 work were assessed at 26 weeks, with extension observations to 52 weeks in some analyses. Benefits on visceral fat were treatment-dependent in follow-up discussions. Timelines refer to trial populations with HIV-associated central fat accumulation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of tesamorelin?\u003c\/strong\u003e\u003cbr\u003eAs a peptide GHRH analog, plasma persistence is short; pharmacodynamic effects run through GH secretion and IGF-1 elevation lasting longer than the parent peptide's plasma spike. Cite clinical pharmacology references for numeric half-life values.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan tesamorelin be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eEvidence-based protocols study it as a single GH-axis agent. Stacking with CJC-1295, ipamorelin, or exogenous GH overlaps pathways and is not how pivotal trials were run. Research clarity favors monotherapy plus defined background care.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20554713\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25038357\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22298602\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:27-07:00","created_at":"2026-07-26T21:19:31-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Oral Sprays","tags":["15mL Oral Spray","99%+ Purity","Oral Sprays","Pre-Mixed"],"variants":[{"id":44076219924567,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-TESAMORELIN-ORAL-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"168.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712770687063,"created_at":"2026-07-26T21:19:31-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35722611032151,"created_at":"2026-08-01T14:56:53-07:00","position":1,"updated_at":"2026-08-01T14:56:54-07:00","product_id":7712770687063,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-tesamorelin-10mg.png?v=1785621414","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712770654295,"title":"NAD+ Oral Spray","handle":"nad-oral","body_html":"\u003ch3\u003eNAD+ — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized NAD+ vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eredox coenzyme and NAD biology research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is not a peptide; it is a nucleotide-derived coenzyme used in virtually every cell. Research interest centers on its role in redox reactions, mitochondrial metabolism, sirtuin signaling, PARP activity, and age-associated changes in cellular energy handling. Education pages often group NAD+ with peptide protocols because it is sold in similar lyophilized formats, but mechanistically it belongs to metabolism and coenzyme biology.\u003c\/p\u003e\u003cp\u003ePublished human work most often studies NAD+ precursors such as nicotinamide riboside or nicotinamide mononucleotide, while direct NAD+ material appears in more limited pharmacokinetic and infusion-oriented discussions. Any research-grade NAD+ powder is Research Use Only and is not the same thing as a regulated drug product. Reported ranges below are reference points from published precursor or NAD-related literature, not instructions for use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eNAD+ cycles between oxidized and reduced forms to shuttle electrons through glycolysis, the TCA cycle, and oxidative phosphorylation. It also serves as a substrate for enzymes including sirtuins, PARPs, CD38, and other NAD-consuming systems. When NAD+ availability changes, downstream effects can include altered mitochondrial respiration, DNA damage signaling, inflammatory tone, and cellular stress responses. Researchers study both direct NAD+ and precursor strategies because cells tightly regulate NAD synthesis, salvage, and consumption.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emitochondrial function\u003c\/li\u003e\n\u003cli\u003eaging biology\u003c\/li\u003e\n\u003cli\u003eredox metabolism\u003c\/li\u003e\n\u003cli\u003ecellular stress response\u003c\/li\u003e\n\u003cli\u003eNAD precursor pharmacology\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNAD+ is studied by mitochondrial biologists, aging researchers, nutrition scientists, and pharmacologists. Clinical investigators more commonly study oral NAD+ precursors, while analytical labs examine NAD+ handling, stability, and compartment-specific measurement.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mg – 1000 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eHuman oral nicotinamide riboside studies commonly cited in NAD+ precursor literature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mg\u003c\/td\u003e\n\u003ctd\u003esingle study dose\u003c\/td\u003e\n\u003ctd\u003eoral\u003c\/td\u003e\n\u003ctd\u003eAcute human cerebral NAD+ measurement study using nicotinamide riboside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized NAD+ is commonly stored frozen and protected from moisture and light; reconstituted material is typically kept refrigerated and used promptly in laboratory settings.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eNAD+ is often discussed beside mitochondrial and recovery-focused compounds, but the strongest literature is on NAD metabolism rather than peptide stacking. Researchers usually separate NAD+ or precursor variables from other interventions so changes in redox markers, methylation demand, and mitochondrial readouts can be interpreted cleanly.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003enicotinamide adenine dinucleotide, oxidized NAD, NAD plus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eContext-dependent; circulating NAD+ and precursors are rapidly metabolized, while downstream NAD pool changes may last longer than plasma exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for NAD+\u003c\/strong\u003e\u003cbr\u003eFor education only: published human studies most often report oral NAD+ precursor amounts, commonly in the hundreds of milligrams to 1 gram daily. That is not a recommendation and is not the same as dosing research-grade NAD+.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for NAD+\u003c\/strong\u003e\u003cbr\u003eResearch suppliers commonly discuss 5-20 mL reconstitution volumes for larger NAD+ vials, depending on target concentration. Reconstitution math is a lab calculation, not a human-use instruction.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily values in the literature usually refer to oral precursors such as nicotinamide riboside. Direct NAD+ protocols vary by research model and should be read from the original paper.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ dosage chart\u003c\/strong\u003e\u003cbr\u003eA useful chart should separate precursor studies, direct NAD+ analytical work, route, concentration, and species. Combining them into one dosing chart can be misleading.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does NAD+ take\u003c\/strong\u003e\u003cbr\u003eSome precursor studies measure NAD-related metabolites within hours, while tissue or functional endpoints are usually assessed over weeks. Timing depends on the assay and model.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNAD+ half life\u003c\/strong\u003e\u003cbr\u003eThere is no single practical half-life for all NAD+ research because NAD+ is rapidly turned over and compartmentalized. Researchers often track metabolite pools rather than plasma half-life alone.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan NAD+ be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied alongside other compounds, but clean protocols isolate variables. Research-use-only material should not be treated as a wellness stack or drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37068054\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eDietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29599478\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39044608\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAcute nicotinamide riboside supplementation increases human cerebral NAD(+) levels in vivo.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:24-07:00","created_at":"2026-07-26T21:19:27-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Oral Sprays","tags":["15mL Oral Spray","99%+ Purity","Oral Sprays","Pre-Mixed"],"variants":[{"id":44076219891799,"title":"500mg","option1":"500mg","option2":null,"option3":null,"sku":"USPL-NAD-ORAL-500MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"125.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712770654295,"created_at":"2026-07-26T21:19:27-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35722610999383,"created_at":"2026-08-01T14:56:48-07:00","position":1,"updated_at":"2026-08-01T14:56:51-07:00","product_id":7712770654295,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/oral-nadplus-500mg.png?v=1785621411","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["500mg"]}]},{"id":7712770588759,"title":"GLP-3RT Oral Spray","handle":"glp-3rt-oral","body_html":"\u003ch3\u003eGLP-3RT — oral format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Oral Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound in an orally administered format rather than a lyophilized vial requiring reconstitution. Oral and sublingual routes are studied for peptides because they remove injection handling from the workflow, while raising well-documented questions about gastrointestinal stability and absorption that vary by compound and formulation. The research summarised below was generated across multiple routes; the reported-amounts table records the route for each figure. Nothing here claims equivalence between routes.\u003c\/p\u003e\u003cp\u003eBecause this oral format is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-3RT vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eIncretin-pathway triple agonist (GIP \/ GLP-1 \/ glucagon receptor)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-3RT (LY3437943) is an investigational peptide agonist engineered to activate three receptors in the incretin\/glucagon family: GIP, GLP-1, and glucagon receptors. It has been evaluated in company-sponsored clinical trials, including a prominent phase 2 obesity study published in the New England Journal of Medicine and earlier multiple-ascending-dose work in type 2 diabetes.\u003c\/p\u003e\u003cp\u003eResearchers focus on GLP-3RT because dual and triple agonists extend the pharmacology already established for GLP-1 receptor agonists. In the phase 2 obesity trial, once-weekly subcutaneous escalation regimens produced substantial, dose-dependent mean body-weight reductions over 48 weeks compared with placebo, alongside metabolic marker changes typical of this class. Gastrointestinal adverse events were the most frequently discussed tolerability theme, consistent with incretin mimetics.\u003c\/p\u003e\u003cp\u003eEducational dosage content should cite trial arms and titration schedules as documented research protocols. GLP-3RT remains investigational for the indications studied in those papers and is not framed here as consumer guidance. Research-use discussions of vial sizes outside formal trials must stay clearly separated from labeled clinical development doses.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-3RT simultaneously engages GIP receptor, GLP-1 receptor, and glucagon receptor pathways. GLP-1 receptor activation is associated with enhanced glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. GIP receptor activity adds another incretin axis that may support insulinotropic and adipose-tissue effects in combination regimens. Glucagon receptor engagement is explored for energy-expenditure and hepatic lipid-metabolism contributions. The triple design aims to combine reduced energy intake with metabolic effects not fully captured by GLP-1 agonism alone.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobesity clinical research\u003c\/li\u003e\n\u003cli\u003etype 2 diabetes\u003c\/li\u003e\n\u003cli\u003eincretin pharmacology\u003c\/li\u003e\n\u003cli\u003ebody-weight regulation\u003c\/li\u003e\n\u003cli\u003ecardiometabolic markers\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEndocrinology and obesity-medicine trialists, metabolic pharmacologists, and translational teams comparing multi-receptor agonists with GLP-1 S- or GLP-2T-class agents. Academic groups analyze body-composition and liver-fat secondary endpoints. This audience is clinical-research oriented rather than cosmetic or injury-repair focused.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 2 obesity trial maintenance dose arms (Jastreboff et al., NEJM 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e500 mcg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly (study-defined)\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 1b multiple-ascending-dose work in type 2 diabetes (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eFollow manufacturer or trial pharmacy instructions for investigational product. Research lyophilizates are typically kept refrigerated, protected from light; reconstituted multi-dose research vials are refrigerated and timed to supplier stability limits. Do not freeze reconstituted solutions unless a COA explicitly allows it.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eFormal trials study GLP-3RT as monotherapy against placebo or active comparators, not as part of informal peptide stacks. Combining with other incretin agents would duplicate pathway stimulation and is outside evidence-based research design. Lifestyle and background diabetes medications in trials are protocol-defined, not ad-hoc stacks.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Oral Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3437943, triple agonist, GGG tri-agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eEngineered for once-weekly administration in clinical development (long-acting incretin-class peptide kinetics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eIn the landmark phase 2 obesity trial, participants received once-weekly subcutaneous GLP-3RT with maintenance doses of 1 mg, 4 mg, 8 mg, or 12 mg after escalation at higher strengths. Those figures are documented clinical-research arms, not a consumer recommendation. Always cite the primary NEJM protocol when discussing dose.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eTrial product is pharmacy-prepared; research vials sold as lyophilized powder require label-specific diluent volumes. Choose a diluent volume that makes weekly mg doses easy to measure on an insulin syringe (for example, concentrating so that 0.1-0.5 mL matches the intended mg). Calculate from vial_mg \/ mL.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage per day\u003c\/strong\u003e\u003cbr\u003eClinical development uses weekly—not daily—dosing. Dividing a weekly mg amount into daily micro-doses is not how the phase 2 obesity protocol was written. Educational charts should show mg per week and titration steps.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage chart\u003c\/strong\u003e\u003cbr\u003eA literature-faithful chart lists escalation steps toward 4, 8, or 12 mg weekly maintenance, including the lower 1 mg arm. Higher-dose groups in phase 2 used gradual increases every four weeks to improve gastrointestinal tolerability. Reproduce numbers from the peer-reviewed methods section.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does GLP-3RT take?\u003c\/strong\u003e\u003cbr\u003eIn the 48-week phase 2 obesity study, mean weight-change curves separated over months, with large effects reported by week 48 at higher doses. Early gastrointestinal symptoms, when they occur in incretin trials, often appear during escalation. Timelines are trial endpoints, not guarantees for any individual.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eGLP-3RT was designed as a long-acting molecule compatible with once-weekly subcutaneous dosing. Exact terminal half-life values should be taken from clinical pharmacology sections of sponsor publications rather than informal blogs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan GLP-3RT be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003ePivotal studies evaluate it alone within controlled backgrounds. Stacking with other GLP-1 or GIP agents is not an evidence-based research protocol and may compound mechanism-overlapping effects. Educational sites should discourage casual polypharmacy framing.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is GLP-3RT dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003emg_dose = concentration_mg_per_mL x mL_drawn. If a 20 mg vial is reconstituted with 2 mL, concentration is 10 mg\/mL, so 0.4 mL provides 4 mg. Use a calculator and dual-check units before any research preparation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTriple-Hormone-Receptor Agonist GLP-3RT for Obesity - A Phase 2 Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-3RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:22-07:00","created_at":"2026-07-26T21:19:22-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Oral Sprays","tags":["15mL Oral Spray","99%+ Purity","Oral Sprays","Pre-Mixed"],"variants":[{"id":44076219662423,"title":"20mg","option1":"20mg","option2":null,"option3":null,"sku":"USPL-GLP-3RT-ORAL-20MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247769677911,"product_id":7712770588759,"position":1,"created_at":"2026-09-23T14:22:54-07:00","updated_at":"2026-09-23T14:22:56-07:00","alt":"GLP-3RT Oral Spray 20mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-20mg.png?v=1790198576","variant_ids":[44076219662423]},"available":true,"price":"220.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712770588759,"created_at":"2026-07-26T21:19:22-07:00","updated_at":"2026-09-23T23:45:45-07:00"},{"id":44076811878487,"title":"40mg","option1":"40mg","option2":null,"option3":null,"sku":"USPL-GLP-3RT-ORAL-40MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247770300503,"product_id":7712770588759,"position":2,"created_at":"2026-09-23T14:22:59-07:00","updated_at":"2026-09-23T14:23:00-07:00","alt":"GLP-3RT Oral Spray 40mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-40mg.png?v=1790198580","variant_ids":[44076811878487]},"available":true,"price":"350.00","grams":0,"compare_at_price":null,"position":2,"product_id":7712770588759,"created_at":"2026-07-27T03:10:20-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":36247769677911,"created_at":"2026-09-23T14:22:54-07:00","position":1,"updated_at":"2026-09-23T14:22:56-07:00","product_id":7712770588759,"variant_ids":[44076219662423],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-20mg.png?v=1790198576","width":1254,"height":1254},{"id":36247770300503,"created_at":"2026-09-23T14:22:59-07:00","position":2,"updated_at":"2026-09-23T14:23:00-07:00","product_id":7712770588759,"variant_ids":[44076811878487],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-oral-40mg.png?v=1790198580","width":1254,"height":1254}],"options":[{"name":"Strength","position":1,"values":["20mg","40mg"]}]},{"id":7712770523223,"title":"Semax \/ Selank Nasal Spray","handle":"semax-selank-nasal","body_html":"\u003ch3\u003eSemax, Selank — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized Semax, Selank vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003eSemax \/ Selank Nasal Spray combines Semax and Selank. Each component is summarised below as it appears in the published literature.\u003c\/p\u003e\u003ch4\u003eSemax\u003c\/h4\u003e\u003cp\u003e\u003cem\u003eSynthetic ACTH(4-10) heptapeptide nootropic \/ neuroprotective research peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSemax is a synthetic heptapeptide analogue of ACTH(4-10) with a Pro-Gly-Pro extension that improves stability relative to the native fragment. It has a long research history in Russian neuroscience for nootropic, neuroprotective, and cerebrovascular questions, with intranasal delivery as the dominant route.\u003c\/p\u003e\u003cp\u003eIndexed studies examine brain penetration after nasal dosing, membrane binding and biodegradation, BDNF-related signaling, and clinical-research use in acute ischemic stroke settings where multi-milligram daily intranasal totals were tested. Western large-scale replication is more limited than the domestic literature base.\u003c\/p\u003e\u003cp\u003eFor dosage education, distinguish animal mcg\/kg work, human stroke-trial milligram schedules, and lower-microgram nootropic research-chemical practices discussed online. Only documented literature ranges are emphasized here, under research-use-only framing.\u003c\/p\u003e\u003ch4\u003eSelank\u003c\/h4\u003e\u003cp\u003e\u003cem\u003esynthetic heptapeptide anxiolytic research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSelank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro sequence. Research has examined anxiolytic-like behavior, cognitive endpoints, cytokine signaling, monoamine systems, and gene-expression changes related to GABAergic neurotransmission. Much of the literature comes from Russian research groups and includes both clinical and preclinical designs.\u003c\/p\u003e\u003cp\u003eEducation content should keep Selank in research-use framing. It is not an FDA-approved drug product, and research-grade Selank is Research Use Only and not for human consumption. Reported ranges below reflect published human or animal study contexts where available and should not be treated as a protocol.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003ch4\u003eSemax\u003c\/h4\u003e\u003cp\u003eSemax does not act like a classical long-acting endocrine ACTH drug at therapeutic glucocorticoid doses. Research points to rapid CNS availability after intranasal dosing, specific binding interactions, proteolytic processing to shorter fragments, and downstream effects on neurotrophic systems including BDNF protein levels in animal work. Functional effects can outlast intact peptide concentrations because of gene-expression and network-level changes.\u003c\/p\u003e\u003ch4\u003eSelank\u003c\/h4\u003e\u003cp\u003eSelank is studied as a tuftsin analog with neuroimmune and neuromodulatory effects. Published work links it to GABAergic gene-expression changes, monoamine metabolism, cytokine modulation, and anxiolytic-like behavioral outcomes. Unlike a single-receptor sedative model, Selank appears in the literature as a multi-pathway peptide with immune and CNS dimensions. That makes endpoint selection and comparator choice important in research design.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003enootropic and cognitive neuroscience\u003c\/li\u003e\n\u003cli\u003eischemic stroke recovery research\u003c\/li\u003e\n\u003cli\u003eBDNF and neurotrophic signaling\u003c\/li\u003e\n\u003cli\u003eintranasal peptide delivery\u003c\/li\u003e\n\u003cli\u003eACTH fragment structure-activity studies\u003c\/li\u003e\n\u003cli\u003eanxiety-model behavior\u003c\/li\u003e\n\u003cli\u003eGABAergic signaling\u003c\/li\u003e\n\u003cli\u003eneuroimmune modulation\u003c\/li\u003e\n\u003cli\u003ecognitive research\u003c\/li\u003e\n\u003cli\u003ecytokine response\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNeuropharmacology labs, stroke-research clinicians in regions where Semax was developed, and blood-brain-barrier delivery groups are the primary audiences. Cognitive-enhancement communities drive search traffic, but legitimate content should stay anchored to peer-reviewed neuroscience rather than lifestyle dosing culture.\u003c\/p\u003e\u003cp\u003eSelank is studied by neuropharmacologists, behavioral neuroscience groups, psychopharmacology researchers, and immunology-focused peptide labs. Translational reviewers pay close attention to country of origin, formulation, route, and trial design.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemax\u003c\/td\u003e\n\u003ctd\u003e12 mg – 18 mg\u003c\/td\u003e\n\u003ctd\u003edaily totals over 5–10 days\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eHuman acute ischemic stroke clinical research (intranasal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemax\u003c\/td\u003e\n\u003ctd\u003e200 mcg – 600 mcg\u003c\/td\u003e\n\u003ctd\u003e1–2 times daily\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommonly cited nootropic research-chemical discussions (not equivalent to stroke-trial dosing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelank\u003c\/td\u003e\n\u003ctd\u003e900 mcg – 2.7 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eClinical intranasal Selank literature commonly discusses sub-milligram to milligram daily exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelank\u003c\/td\u003e\n\u003ctd\u003e100 mcg – 300 mcg\u003c\/td\u003e\n\u003ctd\u003edaily course in animal protocols\u003c\/td\u003e\n\u003ctd\u003eintraperitoneal or intranasal in animal studies\u003c\/td\u003e\n\u003ctd\u003eRat behavioral research with Selank\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003ch4\u003eSemax\u003c\/h4\u003e\u003cp\u003eLyophilized Semax is stored refrigerated or frozen, dry and dark. Reconstituted nasal research solutions are kept cold; sterile technique matters because the route is mucosal.\u003c\/p\u003e\u003ch4\u003eSelank\u003c\/h4\u003e\u003cp\u003eLyophilized Selank is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and handled aseptically.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003ch4\u003eSemax\u003c\/h4\u003e\u003cp\u003eResearch comparisons often place Semax beside Selank (another Russian regulatory peptide) when mapping anxiolytic vs nootropic peptide tools. Stroke papers evaluate it as an add-on to standard care rather than as part of a multi-peptide lifestyle stack. BDNF-pathway discussions sometimes reference other neurotrophic strategies at the mechanistic level only.\u003c\/p\u003e\u003ch4\u003eSelank\u003c\/h4\u003e\u003cp\u003eSelank is often discussed with Semax, nootropic compounds, or anxiolytic comparators, but combined CNS protocols can obscure whether changes reflect peptide effects, stress adaptation, or comparator pharmacology. Research designs should define behavioral endpoints and avoid converting regional clinical literature into general dosing advice.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eMet-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) analogue, MEHFPGP, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, tuftsin analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eSemax: Rapid systemic degradation (minutes-scale peptide clearance reported); functional effects may last many hours — Selank: Not firmly established in widely cited human pharmacokinetic literature; Selank is generally discussed as a short peptide with effects that may outlast measurable exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eSemax: What is the dosage for Semax?\u003c\/strong\u003e\u003cbr\u003eIt depends which literature you mean. Acute stroke research used roughly 12–18 mg\/day intranasally for several days. Secondary nootropic research discussions often cite a few hundred micrograms intranasally. Do not collapse those into one chart without labels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank: what is the dosage for Selank\u003c\/strong\u003e\u003cbr\u003ePublished Selank discussions include intranasal human study contexts and animal mcg\/kg work. These are reference values only, not recommendations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax: How much BAC water for Semax?\u003c\/strong\u003e\u003cbr\u003eFor lyophilized powder, researchers pick a diluent volume that matches nasal spray or drop calibration—commonly 2–3 mL per multi-milligram vial. Some finished research preparations arrive already in solution.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank: how much bacteriostatic water for Selank\u003c\/strong\u003e\u003cbr\u003eSmall research vials are often modeled with 1-2 mL reconstitution volumes. The chosen volume sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax: Semax dosage per day?\u003c\/strong\u003e\u003cbr\u003eStroke-trial daily totals were in the low multi-milligram range. Cognitive research-chemical practice often discusses split intranasal mcg doses once or twice daily. Route in both cases is typically nasal, not subcutaneous.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank: Selank dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily exposure in the literature depends on route, formulation, and study design. Research-grade Selank is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax: Semax dosage chart?\u003c\/strong\u003e\u003cbr\u003eA careful chart separates (1) animal mcg\/kg data, (2) human stroke mg\/day protocols, and (3) lower mcg secondary references. Mixing them without context creates false precision.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank: Selank dosage chart\u003c\/strong\u003e\u003cbr\u003eA responsible chart should separate human intranasal study references from animal per-kg experiments and clearly label all values as research context.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11517472\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16635254\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSemax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16523722\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9173745\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30255741\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003ePeptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25176261\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26924987\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:16-07:00","created_at":"2026-07-26T21:19:14-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed Blend"],"variants":[{"id":44076219596887,"title":"15\/15mg","option1":"15\/15mg","option2":null,"option3":null,"sku":"USPL-SEMAX-SELANK-NASAL-15-15MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"165.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712770523223,"created_at":"2026-07-26T21:19:14-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717375557719,"created_at":"2026-08-01T00:32:20-07:00","position":1,"updated_at":"2026-08-01T00:32:21-07:00","product_id":7712770523223,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-semax-selank-15mg-15mg_efbcb023-0f98-488a-a76a-ce6d4906ba58.png?v=1785569541","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["15\/15mg"]}]},{"id":7712770097239,"title":"GHK-Cu Nasal Spray","handle":"ghk-cu-nasal","body_html":"\u003ch3\u003eGHK-Cu — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GHK-Cu vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eCopper-binding tripeptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. It appears in human plasma, saliva, and urine, and circulating levels are reported to decline with age. In research settings it is treated as a small signaling peptide that can shuttle copper into cells and influence gene programs tied to extracellular matrix turnover.\u003c\/p\u003e\u003cp\u003eInvestigators study GHK-Cu because multiple cell-culture and animal models link it to organized collagen and glycosaminoglycan synthesis, balanced matrix metalloproteinase activity, and support for angiogenesis during tissue remodeling. Reviews by Pickart and colleagues summarize effects across skin regeneration, wound models, and broader protective gene-expression patterns. Most human data involve topical cosmetic or dermatology formulations rather than large injectable trials.\u003c\/p\u003e\u003cp\u003eFor laboratory and research-use-only contexts, GHK-Cu is typically supplied as a lyophilized powder for reconstitution. Published work frames it as a reference compound for studying copper-dependent repair pathways, not as an approved systemic therapy for disease. Any dosage figures discussed on educational pages are literature-reported ranges for reference, not recommendations.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGHK binds Cu2+ with high affinity and can deliver bioavailable copper while acting as a signaling ligand. Reported cellular effects include modulation of TGF-beta and integrin-related pathways, upregulation of collagen, elastin, and proteoglycan synthesis, and coordinated control of MMPs and their inhibitors so matrix breakdown and rebuild stay balanced. Antioxidant and anti-inflammatory actions are also described, including support for superoxide dismutase activity and reductions in selected pro-inflammatory cytokines in experimental systems. Together these actions position GHK-Cu as a remodeler of the extracellular matrix rather than a simple structural filler.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eskin remodeling\u003c\/li\u003e\n\u003cli\u003ewound healing\u003c\/li\u003e\n\u003cli\u003eextracellular matrix biology\u003c\/li\u003e\n\u003cli\u003ecollagen synthesis\u003c\/li\u003e\n\u003cli\u003eanti-inflammatory signaling\u003c\/li\u003e\n\u003cli\u003eangiogenesis\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eDermatology and wound-healing researchers use GHK-Cu to probe copper-dependent matrix remodeling and fibroblast behavior. Cosmetic scientists evaluate topical formulations for photoaging and barrier metrics. Regenerative-biology labs study its gene-expression footprint in repair models. Interest is strongest among groups working on tissue architecture, not general endocrinology.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e500 mcg – 2 mg\u003c\/td\u003e\n\u003ctd\u003edaily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eCommonly cited in research and compounding reference protocols for subcutaneous investigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003e1-2 times daily\u003c\/td\u003e\n\u003ctd\u003etopical\u003c\/td\u003e\n\u003ctd\u003eTopical dermatology and cosmetic research formulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eKeep lyophilized vials refrigerated or frozen per supplier COA, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within the stability window stated by the supplier, commonly cited as up to 30 days when kept cold and uncontaminated.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eIn research catalogs GHK-Cu often appears alongside BPC-157 and TB-500\/thymosin beta-4 in multi-peptide repair blends (for example Glow or Klow) because the components target complementary matrix, angiogenic, and inflammatory pathways. It is also studied next to topical retinoids or growth-factor serums in dermatology work. Stacking discussions should stay per-component: each peptide has its own concentration math.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eCopper Peptide, GHK-Copper, Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort systemic half-life reported for the free peptide (on the order of minutes to about an hour in secondary sources); topical residence depends on vehicle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for GHK-Cu peptide?\u003c\/strong\u003e\u003cbr\u003eThere is no single universal clinical dose for research-grade GHK-Cu injectables. Secondary research-protocol summaries commonly cite roughly 500-2,000 mcg (0.5-2 mg) subcutaneously per day, while topical work uses percent-strength creams rather than mcg injections. Treat published figures as reference ranges from literature and lab practice, not personal medical advice. Use a reconstitution calculator to convert vial milligrams and diluent volume into mcg per unit.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for GHK-Cu?\u003c\/strong\u003e\u003cbr\u003eCommon research vial sizes are 50 mg or 100 mg. Adding 3 mL or 5 mL of bacteriostatic water are frequent choices because they yield easy insulin-syringe math. Example: 50 mg in 5 mL gives 10 mg\/mL, so 0.1 mL (10 units on a U-100 syringe) equals 1,000 mcg. Always confirm your vial label and calculate from actual mg and mL.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGHK-Cu dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily subcutaneous amounts most often discussed in research-protocol writeups fall near 1 mg\/day, with a broader cited band of about 0.5-2 mg. Frequency is usually once daily in those summaries. Human injectable dose-finding literature is thinner than the topical evidence base, so ranges should be read as commonly reported reference values.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs there a GHK-Cu dosage chart?\u003c\/strong\u003e\u003cbr\u003eA practical chart maps reconstituted concentration to syringe units. If a 50 mg vial is mixed with 5 mL bac water (10 mg\/mL), then 5 units = 500 mcg, 10 units = 1,000 mcg, and 20 units = 2,000 mcg on a U-100 insulin syringe. Build the chart from your exact vial size and diluent volume rather than copying a generic image.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does GHK-Cu take to show research endpoints?\u003c\/strong\u003e\u003cbr\u003eTopical dermatology studies often run 8-12 weeks when measuring wrinkle, density, or elasticity endpoints. Preclinical wound models can show earlier histologic changes. Timeline depends on model, route, concentration, and outcome measure. Educational pages should not promise personal results.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of GHK-Cu?\u003c\/strong\u003e\u003cbr\u003eThe free tripeptide is generally described as short-acting in systemic circulation, with secondary sources often placing clearance on the order of under an hour. Copper binding, tissue uptake, and topical vehicles change effective duration at the application site. Primary PK packages for every research route are not uniform.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan GHK-Cu be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003eResearch blends frequently pair GHK-Cu with BPC-157 and TB-500, and sometimes KPV, to cover matrix remodeling plus cytoprotection and actin-related cell migration. Combination products still require per-component dose accounting. Compatibility in a multi-peptide vial does not equal clinical endorsement of a stack.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is GHK-Cu dosage calculated after reconstitution?\u003c\/strong\u003e\u003cbr\u003eDose (mcg) = concentration (mg\/mL) x volume drawn (mL) x 1,000. Concentration = vial_mg \/ diluent_mL. Example: 100 mg \/ 5 mL = 20 mg\/mL; drawing 0.05 mL delivers 1 mg (1,000 mcg). Point researchers to an on-site peptide dosage calculator to avoid unit errors.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26236730\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18644225\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThe human tri-peptide GHK and tissue remodeling.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29986520\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/3169264\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eStimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:13-07:00","created_at":"2026-07-26T21:11:38-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed"],"variants":[{"id":44076218843223,"title":"50mg","option1":"50mg","option2":null,"option3":null,"sku":"USPL-GHK-CU-NASAL-50MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712770097239,"created_at":"2026-07-26T21:11:38-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717375197271,"created_at":"2026-08-01T00:32:11-07:00","position":1,"updated_at":"2026-08-01T00:32:13-07:00","product_id":7712770097239,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-ghk-cu-50mg_77164abd-4b1b-4897-85ad-3f2590b83534.png?v=1785569533","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["50mg"]}]},{"id":7712769998935,"title":"BPC-157 \/ TB-500 Nasal Spray","handle":"bpc-tb-nasal","body_html":"\u003ch3\u003eBPC-157, TB-500 — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized BPC-157, TB-500 vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003eBPC-157 \/ TB-500 Nasal Spray combines BPC-157 and TB-500. Each component is summarised below as it appears in the published literature.\u003c\/p\u003e\u003ch4\u003eBPC-157\u003c\/h4\u003e\u003cp\u003e\u003cem\u003esynthetic gastric pentadecapeptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eBPC-157 is a 15-amino-acid peptide derived from a body-protection-compound sequence associated with gastric juice research. Most published work is preclinical, with animal models examining wound repair, tendon and ligament injury, gastrointestinal integrity, vascular responses, and nitric-oxide-system interactions. Human evidence is much thinner than internet discussion suggests.\u003c\/p\u003e\u003cp\u003eBecause the literature is dominated by rodent and other animal models, BPC-157 education needs careful framing. Research-grade BPC-157 is Research Use Only and is not an approved drug product. Reported ranges below reflect published animal-study exposure styles and should not be converted into human protocols.\u003c\/p\u003e\u003ch4\u003eTB-500\u003c\/h4\u003e\u003cp\u003e\u003cem\u003eActin-binding repair peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eTB-500 is a synthetic research peptide associated with the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide abundant in platelets and wound fluid. In laboratory and preclinical models, Tβ4 and related fragments have been examined for roles in cell motility, angiogenesis, inflammation resolution, and extracellular-matrix organization after injury.\u003c\/p\u003e\u003cp\u003eResearchers study TB-500 because full-length Tβ4 has a long experimental record in dermal wound models, cardiac injury paradigms, corneal repair work, and regenerative-biology reviews. The synthetic fragment is used as a more practical research tool when investigators want to probe actin-cytoskeleton and repair-associated signaling without working with the entire native protein.\u003c\/p\u003e\u003cp\u003eAll material discussed here is Research Use Only (RUO). It is not a drug product, not approved by the FDA for human use, and not intended for human consumption, clinical treatment, or diagnostic procedures. Published dosage figures below are literature or commonly cited research-protocol references, not recommendations.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003ch4\u003eBPC-157\u003c\/h4\u003e\u003cp\u003eBPC-157 is studied for interactions with cytoprotective pathways, angiogenesis-related signaling, nitric oxide balance, and tissue-response networks. Preclinical papers describe effects on vascular integrity, growth-factor expression, inflammatory responses, and gastrointestinal mucosal resilience. The exact receptor-level mechanism is not settled, and much of the evidence comes from model-specific injury systems. That uncertainty is why species, route, and endpoint matter so much in BPC-157 interpretation.\u003c\/p\u003e\u003ch4\u003eTB-500\u003c\/h4\u003e\u003cp\u003eThymosin beta-4 sequesters G-actin and helps regulate actin polymerization, which influences cytoskeletal remodeling and cell migration. Related domains have been linked in the literature to pro-angiogenic signaling, reduced inflammatory tone at injury sites, and shifts in fibrosis-related cell phenotypes. TB-500 is studied as a compact surrogate for key actin-binding and repair-associated activities of the parent peptide, though fragment-versus-full-length differences remain an active research question.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003ewound healing models\u003c\/li\u003e\n\u003cli\u003etendon and ligament research\u003c\/li\u003e\n\u003cli\u003egastrointestinal integrity\u003c\/li\u003e\n\u003cli\u003eangiogenesis signaling\u003c\/li\u003e\n\u003cli\u003enitric oxide pathways\u003c\/li\u003e\n\u003cli\u003etissue repair and wound models\u003c\/li\u003e\n\u003cli\u003ecell migration and actin dynamics\u003c\/li\u003e\n\u003cli\u003eangiogenesis\u003c\/li\u003e\n\u003cli\u003ecardiac injury models\u003c\/li\u003e\n\u003cli\u003eanti-fibrotic and inflammation-resolution pathways\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eBPC-157 is studied mainly by preclinical pharmacology groups, gastrointestinal researchers, sports-medicine reviewers, and analytical laboratories. Human clinical researchers generally treat the evidence base as preliminary and not interchangeable with approved peptide therapeutics.\u003c\/p\u003e\u003cp\u003eInterest is highest among regenerative-biology, sports-medicine research, and wound-healing laboratories that model soft-tissue injury, angiogenesis, or cytoskeletal control of repair. Comparative work also appears in cardiac and corneal injury literature focused on Tβ4 biology rather than TB-500 as a clinical agent.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBPC-157\u003c\/td\u003e\n\u003ctd\u003e0.01 mcg – 10 mcg\u003c\/td\u003e\n\u003ctd\u003evaries by animal model\u003c\/td\u003e\n\u003ctd\u003eintraperitoneal, oral, topical, or local in animal studies\u003c\/td\u003e\n\u003ctd\u003ePreclinical BPC-157 animal studies frequently report ng\/kg to mcg\/kg exposure bands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBPC-157\u003c\/td\u003e\n\u003ctd\u003e10 mcg\u003c\/td\u003e\n\u003ctd\u003emodel-dependent\u003c\/td\u003e\n\u003ctd\u003eanimal-study routes vary\u003c\/td\u003e\n\u003ctd\u003eRodent injury and gastrointestinal models often cite 10 mcg\/kg as an experimental exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB-500\u003c\/td\u003e\n\u003ctd\u003e2 mg – 5 mg\u003c\/td\u003e\n\u003ctd\u003etwice weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eCommonly cited in research-protocol summaries for synthetic TB-500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB-500\u003c\/td\u003e\n\u003ctd\u003e2 mg – 2.5 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eMaintenance-style ranges reported in research-community protocols\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB-500\u003c\/td\u003e\n\u003ctd\u003e42 mg – 1260 mg\u003c\/td\u003e\n\u003ctd\u003esingle or daily multi-dose cohorts\u003c\/td\u003e\n\u003ctd\u003eintravenous\u003c\/td\u003e\n\u003ctd\u003eHuman intravenous Tβ4 safety study (full-length peptide, not TB-500 fragment)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003ch4\u003eBPC-157\u003c\/h4\u003e\u003cp\u003eLyophilized BPC-157 is commonly stored frozen or refrigerated, dry, and protected from light; reconstituted research solutions are usually refrigerated and handled aseptically.\u003c\/p\u003e\u003ch4\u003eTB-500\u003c\/h4\u003e\u003cp\u003eKeep lyophilized vials refrigerated or frozen, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within the timeframe specified by the laboratory protocol, typically days to a few weeks.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003ch4\u003eBPC-157\u003c\/h4\u003e\u003cp\u003eBPC-157 is commonly paired in online discussion with TB-500, GHK-Cu, or recovery-focused compounds, but those combinations outrun the human evidence. Research protocols should isolate injury model, route, and endpoint before combining peptides, especially when the base evidence is preclinical.\u003c\/p\u003e\u003ch4\u003eTB-500\u003c\/h4\u003e\u003cp\u003eIn research discussions, TB-500 is frequently examined alongside BPC-157 because both appear in soft-tissue repair literature, though through different proposed pathways. Some protocols also pair actin-repair work with growth-hormone secretagogue or GHRH-analog models when the experimental question involves recovery physiology rather than a single molecular target.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eBody Protection Compound 157, PL 14736, stable gastric pentadecapeptide BPC 157, Thymosin Beta-4 fragment, Tβ4 fragment, LKKTETQ motif peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eBPC-157: Not well established for human use; published discussions emphasize stability in gastric-juice-related contexts and model-specific exposure rather than a clinical half-life. — TB-500: ~2-3 hours reported for related Tβ4 biology; tissue effects may outlast plasma half-life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eBPC-157: what is the dosage for BPC-157\u003c\/strong\u003e\u003cbr\u003ePublished BPC-157 research is mostly animal work, often reported as ng\/kg or mcg\/kg. Those values are reference information and are not human dosing instructions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTB-500: What is TB-500 peptide dosage in research contexts?\u003c\/strong\u003e\u003cbr\u003eSecondary research summaries most often cite about 2,000-5,000 mcg twice weekly during higher-intensity phases, with lower once-weekly amounts afterward. These are reference figures from protocol literature, not medical advice.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eBPC-157: how much bacteriostatic water for BPC-157\u003c\/strong\u003e\u003cbr\u003eCommon research examples use 1-3 mL for 5-10 mg vials. Reconstitution volume changes concentration only.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTB-500: Is TB-500 the same as thymosin beta-4?\u003c\/strong\u003e\u003cbr\u003eNot exactly. TB-500 is a synthetic peptide related to the actin-binding region of thymosin beta-4. Full-length Tβ4 is the native 43-amino-acid peptide used in many primary papers.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eBPC-157: BPC-157 dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily BPC-157 schedules in online charts are not the same as published study protocols. A literature-based answer must specify species, route, and model.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTB-500: How is TB-500 typically reconstituted for lab use?\u003c\/strong\u003e\u003cbr\u003eResearch vials of 5-10 mg are commonly reconstituted with 2-3 mL bacteriostatic water so insulin-syringe graduations map cleanly to mcg amounts. Exact solvent volume depends on the assay design.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eBPC-157: BPC-157 dosage chart\u003c\/strong\u003e\u003cbr\u003eA responsible chart should separate animal-study mcg\/kg values from vial concentration math and should avoid presenting either as a recommendation.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTB-500: What pathways make TB-500 interesting to researchers?\u003c\/strong\u003e\u003cbr\u003eMost interest centers on actin sequestration, cell migration, angiogenesis, and inflammation-resolution signaling observed with Tβ4-family peptides in injury models.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34267654\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eStable Gastric Pentadecapeptide BPC 157 and Wound Healing.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21548867\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eStable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23755725\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eStable gastric pentadecapeptide BPC 157-NO-system relation.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22074294\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/10469335\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThymosin beta4 accelerates wound healing.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20536453\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAnimal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23050815\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThe regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20536472\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:10-07:00","created_at":"2026-07-26T21:11:31-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed Blend"],"variants":[{"id":44076218712151,"title":"10\/10mg","option1":"10\/10mg","option2":null,"option3":null,"sku":"USPL-BPC-TB-NASAL-10-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"110.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769998935,"created_at":"2026-07-26T21:11:32-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717373526103,"created_at":"2026-08-01T00:32:02-07:00","position":1,"updated_at":"2026-08-01T00:32:04-07:00","product_id":7712769998935,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-bpc-157-tb-500-10mg-10mg_6ebe38ea-9cf1-4fcd-bd51-0250bc98938b.png?v=1785569524","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10\/10mg"]}]},{"id":7712769966167,"title":"PT-141 \/ Oxytocin Nasal Spray","handle":"pt-141-oxytocin-nasal","body_html":"\u003ch3\u003ePT-141 (Bremelanotide), Oxytocin — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized PT-141 (Bremelanotide), Oxytocin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003ePT-141 \/ Oxytocin Nasal Spray combines PT-141 (Bremelanotide) and Oxytocin. Each component is summarised below as it appears in the published literature.\u003c\/p\u003e\u003ch4\u003ePT-141 (Bremelanotide)\u003c\/h4\u003e\u003cp\u003e\u003cem\u003emelanocortin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.\u003c\/p\u003e\u003cp\u003eBremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.\u003c\/p\u003e\u003ch4\u003eOxytocin\u003c\/h4\u003e\u003cp\u003e\u003cem\u003eEndogenous nonapeptide hormone\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eOxytocin is an endogenous nonapeptide synthesized in the hypothalamus and released by the posterior pituitary. It is among the most thoroughly characterized peptides in human medicine because of long-standing obstetric uses, while a parallel research literature explores social cognition, stress responsivity, metabolic signals, and pain processing.\u003c\/p\u003e\u003cp\u003ePharmacologically, oxytocin is notable for a very short plasma half-life after intravenous dosing, which is why obstetric protocols often rely on controlled infusions. Research outside obstetrics frequently uses intranasal delivery when central nervous system questions are in view; subcutaneous routes appear in selected experimental pain and animal studies. A 2024 randomized trial reported that a low microgram-range subcutaneous dose modulated heat-pain ratings in healthy adults, adding a peer-reviewed SC data point.\u003c\/p\u003e\u003cp\u003eEducational dosage content must separate approved obstetric regimens, intranasal social-neuroscience doses (often 24 IU in experimental paradigms), and research-peptide vial math. This page is research-and-education oriented with research-use-only framing for non-labeled contexts—not a guide for unsupervised hormone use.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003ch4\u003ePT-141 (Bremelanotide)\u003c\/h4\u003e\u003cp\u003ePT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.\u003c\/p\u003e\u003ch4\u003eOxytocin\u003c\/h4\u003e\u003cp\u003eOxytocin binds the G protein-coupled oxytocin receptor (OXTR), expressed in uterus, mammary tissue, brain circuits, and peripheral sites. Receptor activation engages phospholipase C and calcium-dependent pathways that drive uterine smooth-muscle contraction and milk ejection in physiologic contexts. Centrally, OXTR signaling modulates social salience, anxiety-related circuits, and autonomic tone in experimental paradigms. Peripheral analgesic effects discussed in recent SC research may involve local receptor mechanisms in addition to any central actions.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin signaling\u003c\/li\u003e\n\u003cli\u003eMC4R neurobiology\u003c\/li\u003e\n\u003cli\u003esexual arousal pharmacodynamics\u003c\/li\u003e\n\u003cli\u003eCNS peptide signaling\u003c\/li\u003e\n\u003cli\u003epeptide pharmacokinetics\u003c\/li\u003e\n\u003cli\u003eobstetric pharmacology\u003c\/li\u003e\n\u003cli\u003esocial neuroscience\u003c\/li\u003e\n\u003cli\u003estress and affiliation biology\u003c\/li\u003e\n\u003cli\u003eexperimental pain modulation\u003c\/li\u003e\n\u003cli\u003emetabolic and autonomic research\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.\u003c\/p\u003e\u003cp\u003eObstetric clinical pharmacologists, affective and social neuroscientists, pain researchers, and endocrinology labs mapping OXTR distribution all work with oxytocin. Behavioral science groups dominate the intranasal literature. Peptide-education audiences often arrive via research-vial contexts and need help distinguishing IU obstetric dosing from mcg research vials.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePT-141 (Bremelanotide)\u003c\/td\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle study administration\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous PT-141 clinical pharmacology study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePT-141 (Bremelanotide)\u003c\/td\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle crossover study administration\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eIntranasal PT-141 plus sildenafil study in men with erectile dysfunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePT-141 (Bremelanotide)\u003c\/td\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003eas labeled for the approved product\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eFDA-approved bremelanotide product label context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOxytocin\u003c\/td\u003e\n\u003ctd\u003e4 mcg\u003c\/td\u003e\n\u003ctd\u003esingle-dose experimental\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eExperimental subcutaneous research (example peer-reviewed human SC study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOxytocin\u003c\/td\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003estudy-defined (often single or limited repeated sessions)\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommon intranasal experimental neuroscience paradigms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOxytocin\u003c\/td\u003e\n\u003ctd\u003e10 mcg – 100 mcg\u003c\/td\u003e\n\u003ctd\u003evaries widely in informal sources\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSecondary research-peptide discussions of SC ranges (less standardized than obstetric IV\/IM labeling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003ch4\u003ePT-141 (Bremelanotide)\u003c\/h4\u003e\u003cp\u003eResearch-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.\u003c\/p\u003e\u003ch4\u003eOxytocin\u003c\/h4\u003e\u003cp\u003eProtect from heat and light; refrigerated storage is standard for oxytocin preparations. Reconstituted research solutions should be kept cold, tightly capped, and discarded per stability guidance. Oxytocin is oxidation- and temperature-sensitive relative to hardier lyophilized research peptides.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003ch4\u003ePT-141 (Bremelanotide)\u003c\/h4\u003e\u003cp\u003ePT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.\u003c\/p\u003e\u003ch4\u003eOxytocin\u003c\/h4\u003e\u003cp\u003eNeuroscience studies typically administer oxytocin alone when measuring social or stress endpoints. Combining with other neuropeptides confounds interpretation of OXTR-specific effects. Obstetric clinical protocols likewise do not stack research peptides; they follow labeled labor or postpartum pathways under medical supervision.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003ebremelanotide, PT-141, melanocortin receptor agonist, OXT, OT, alpha-hypophamine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003ePT-141 (Bremelanotide): Bremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts. — Oxytocin: About 1-6 minutes plasma half-life after IV administration commonly cited; effective central effects after intranasal dosing are discussed on longer behavioral timescales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ePT-141 (Bremelanotide): what is the dosage for PT-141\u003c\/strong\u003e\u003cbr\u003ePublished PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin: What is the dosage for oxytocin peptide?\u003c\/strong\u003e\u003cbr\u003eIt depends entirely on context. Obstetric labeling uses IU for IV infusion or IM injection under clinical care. Social neuroscience often studies about 24 IU intranasally. A 2024 pain trial used 4 mcg subcutaneously as a single experimental dose. Research-vial mcg charts are not interchangeable with labor-and-delivery orders.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 (Bremelanotide): how much bacteriostatic water for PT-141\u003c\/strong\u003e\u003cbr\u003eReconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin: How much bac water for oxytocin?\u003c\/strong\u003e\u003cbr\u003eFor a 10 mg research vial, even 2-3 mL produces a very concentrated solution relative to low-mcg experimental targets, so serial dilution may be required for accurate microgram dosing. Document every dilution step. Clinical products arrive with their own diluents and concentrations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 (Bremelanotide): PT-141 dosage per day\u003c\/strong\u003e\u003cbr\u003ePT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin: Oxytocin dosage per day\u003c\/strong\u003e\u003cbr\u003eThere is no general per-day research standard analogous to once-weekly incretins. Obstetric use is continuous or event-driven. Behavioral studies are usually session-based. Chronic daily SC schedules online should be treated skeptically without primary support.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 (Bremelanotide): PT-141 dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOxytocin: Oxytocin dosage chart\u003c\/strong\u003e\u003cbr\u003eSeparate charts by route: IU for labeled obstetric products, IU for intranasal experimental sprays, and mcg for reconstituted research vials. Include the conversion note that product-specific IU-mcg relationships must be confirmed on the label.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16839319\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15833522\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38642595\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSubcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8568623\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eBioavailability and pharmacokinetics of sublingual oxytocin in male volunteers.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31286109\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLong-Acting and Selective Oxytocin Peptide Analogs Show Antidiabetic and Antiobesity Effects in Male Mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:07-07:00","created_at":"2026-07-26T21:11:26-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed Blend"],"variants":[{"id":44076218679383,"title":"5\/10mg","option1":"5\/10mg","option2":null,"option3":null,"sku":"USPL-PT-141-OXYTOCIN-NASAL-5-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"128.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769966167,"created_at":"2026-07-26T21:11:26-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35717370085463,"created_at":"2026-08-01T00:31:54-07:00","position":1,"updated_at":"2026-08-01T00:31:56-07:00","product_id":7712769966167,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/nasal-pt-141-oxytocin-5mg-10mg_01e8883c-f7ba-4381-9296-2aa4645b7bef.png?v=1785569516","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["5\/10mg"]}]},{"id":7712769835095,"title":"GLP-2T Nasal Spray","handle":"glp-2t-nasal","body_html":"\u003ch3\u003eGLP-2T — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-2T vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003edual incretin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is a long-acting peptide engineered to activate both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Large clinical trials have studied once-weekly GLP-2T in metabolic endpoints including glycemic measures, body weight, cardiometabolic markers, and comparative incretin pharmacology.\u003c\/p\u003e\u003cp\u003eGLP-2T has FDA-approved counterparts, including Mounjaro and Zepbound, for their specific approved uses and labeled formulations. Research-grade GLP-2T powder is not Mounjaro or Zepbound, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published trial dose arms or approved-product contexts, not recommendations.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-2T activates GIP and GLP-1 receptors, linking two incretin pathways that influence insulin secretion, glucagon dynamics, gastric emptying, appetite-related signaling, and energy-balance endpoints. Its fatty-acid modification supports prolonged albumin binding and once-weekly exposure in approved-product studies. Research comparisons often evaluate whether dual incretin signaling produces different metabolic and tolerability profiles than selective GLP-1 receptor agonism.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eincretin biology\u003c\/li\u003e\n\u003cli\u003eGIP receptor signaling\u003c\/li\u003e\n\u003cli\u003eGLP-1 receptor signaling\u003c\/li\u003e\n\u003cli\u003emetabolic pharmacology\u003c\/li\u003e\n\u003cli\u003ebody weight and glycemic endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is studied by endocrinologists, obesity researchers, cardiometabolic trialists, pharmacokinetic modelers, and regulatory scientists. Quality and formulation specialists distinguish regulated finished products from research-grade materials because they are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURPASS clinical trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURMOUNT obesity trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eApproved GLP-2T products have label-specific refrigerated storage instructions; research-grade lyophilized material is typically stored frozen or refrigerated per supplier specifications and protected from moisture and light.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eGLP-2T is often compared with GLP-1 receptor agonists, but combining incretin compounds or layering metabolic agents can confound appetite, glucose, gastrointestinal, and body-weight endpoints. Research-grade GLP-2T should never be positioned as a substitute for Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3298176, dual GIP\/GLP-1 receptor agonist, GIP\/GLP-1 agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eApproximately 5 days is commonly cited for GLP-2T in clinical pharmacology and labeling contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for GLP-2T\u003c\/strong\u003e\u003cbr\u003ePublished trials commonly studied 5, 10, and 15 mg once weekly dose arms. Those data describe clinical trial or approved-product contexts, not research-grade material use.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for GLP-2T\u003c\/strong\u003e\u003cbr\u003eResearch reconstitution volumes often use 1-3 mL depending on vial strength and target concentration. This is concentration math only.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage per day\u003c\/strong\u003e\u003cbr\u003eThe major clinical literature uses once-weekly exposure, not daily dosing. Research-grade GLP-2T is RUO and not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should distinguish trial dose arms, approved product titration, and lab concentration examples. These should not be blended.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does GLP-2T take\u003c\/strong\u003e\u003cbr\u003eTrials evaluate metabolic endpoints over weeks to months, while pharmacokinetic steady state depends on its multi-day half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T half life\u003c\/strong\u003e\u003cbr\u003eGLP-2T is commonly cited with an approximate 5-day half-life, supporting once-weekly dosing in approved-product studies.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan GLP-2T be stacked\u003c\/strong\u003e\u003cbr\u003eCombination metabolic research requires careful controls and medical-regulatory distinction. RUO GLP-2T is not Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T versus GLP-1 S Once Weekly in Patients with Type 2 Diabetes.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T Once Weekly for the Treatment of Obesity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35133415\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of Subcutaneous GLP-2T vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:04-07:00","created_at":"2026-07-26T21:11:19-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed"],"variants":[{"id":44076218548311,"title":"40mg","option1":"40mg","option2":null,"option3":null,"sku":"USPL-GLP-2T-NASAL-40MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247768793175,"product_id":7712769835095,"position":1,"created_at":"2026-09-23T14:22:46-07:00","updated_at":"2026-09-23T14:22:48-07:00","alt":"GLP-2T Nasal Spray 40mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-nasal-40mg.png?v=1790198568","variant_ids":[44076218548311]},"available":true,"price":"220.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769835095,"created_at":"2026-07-26T21:11:19-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":36247768793175,"created_at":"2026-09-23T14:22:46-07:00","position":1,"updated_at":"2026-09-23T14:22:48-07:00","product_id":7712769835095,"variant_ids":[44076218548311],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-nasal-40mg.png?v=1790198568","width":1254,"height":1254}],"options":[{"name":"Strength","position":1,"values":["40mg"]}]},{"id":7712769769559,"title":"GLP-3RT Nasal Spray","handle":"glp-3rt-nasal","body_html":"\u003ch3\u003eGLP-3RT — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-3RT vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eIncretin-pathway triple agonist (GIP \/ GLP-1 \/ glucagon receptor)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-3RT (LY3437943) is an investigational peptide agonist engineered to activate three receptors in the incretin\/glucagon family: GIP, GLP-1, and glucagon receptors. It has been evaluated in company-sponsored clinical trials, including a prominent phase 2 obesity study published in the New England Journal of Medicine and earlier multiple-ascending-dose work in type 2 diabetes.\u003c\/p\u003e\u003cp\u003eResearchers focus on GLP-3RT because dual and triple agonists extend the pharmacology already established for GLP-1 receptor agonists. In the phase 2 obesity trial, once-weekly subcutaneous escalation regimens produced substantial, dose-dependent mean body-weight reductions over 48 weeks compared with placebo, alongside metabolic marker changes typical of this class. Gastrointestinal adverse events were the most frequently discussed tolerability theme, consistent with incretin mimetics.\u003c\/p\u003e\u003cp\u003eEducational dosage content should cite trial arms and titration schedules as documented research protocols. GLP-3RT remains investigational for the indications studied in those papers and is not framed here as consumer guidance. Research-use discussions of vial sizes outside formal trials must stay clearly separated from labeled clinical development doses.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-3RT simultaneously engages GIP receptor, GLP-1 receptor, and glucagon receptor pathways. GLP-1 receptor activation is associated with enhanced glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. GIP receptor activity adds another incretin axis that may support insulinotropic and adipose-tissue effects in combination regimens. Glucagon receptor engagement is explored for energy-expenditure and hepatic lipid-metabolism contributions. The triple design aims to combine reduced energy intake with metabolic effects not fully captured by GLP-1 agonism alone.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobesity clinical research\u003c\/li\u003e\n\u003cli\u003etype 2 diabetes\u003c\/li\u003e\n\u003cli\u003eincretin pharmacology\u003c\/li\u003e\n\u003cli\u003ebody-weight regulation\u003c\/li\u003e\n\u003cli\u003ecardiometabolic markers\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEndocrinology and obesity-medicine trialists, metabolic pharmacologists, and translational teams comparing multi-receptor agonists with GLP-1 S- or GLP-2T-class agents. Academic groups analyze body-composition and liver-fat secondary endpoints. This audience is clinical-research oriented rather than cosmetic or injury-repair focused.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 mg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 2 obesity trial maintenance dose arms (Jastreboff et al., NEJM 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e500 mcg – 12 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly (study-defined)\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePhase 1b multiple-ascending-dose work in type 2 diabetes (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eFollow manufacturer or trial pharmacy instructions for investigational product. Research lyophilizates are typically kept refrigerated, protected from light; reconstituted multi-dose research vials are refrigerated and timed to supplier stability limits. Do not freeze reconstituted solutions unless a COA explicitly allows it.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eFormal trials study GLP-3RT as monotherapy against placebo or active comparators, not as part of informal peptide stacks. Combining with other incretin agents would duplicate pathway stimulation and is outside evidence-based research design. Lifestyle and background diabetes medications in trials are protocol-defined, not ad-hoc stacks.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3437943, triple agonist, GGG tri-agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eEngineered for once-weekly administration in clinical development (long-acting incretin-class peptide kinetics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eIn the landmark phase 2 obesity trial, participants received once-weekly subcutaneous GLP-3RT with maintenance doses of 1 mg, 4 mg, 8 mg, or 12 mg after escalation at higher strengths. Those figures are documented clinical-research arms, not a consumer recommendation. Always cite the primary NEJM protocol when discussing dose.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eTrial product is pharmacy-prepared; research vials sold as lyophilized powder require label-specific diluent volumes. Choose a diluent volume that makes weekly mg doses easy to measure on an insulin syringe (for example, concentrating so that 0.1-0.5 mL matches the intended mg). Calculate from vial_mg \/ mL.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage per day\u003c\/strong\u003e\u003cbr\u003eClinical development uses weekly—not daily—dosing. Dividing a weekly mg amount into daily micro-doses is not how the phase 2 obesity protocol was written. Educational charts should show mg per week and titration steps.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-3RT dosage chart\u003c\/strong\u003e\u003cbr\u003eA literature-faithful chart lists escalation steps toward 4, 8, or 12 mg weekly maintenance, including the lower 1 mg arm. Higher-dose groups in phase 2 used gradual increases every four weeks to improve gastrointestinal tolerability. Reproduce numbers from the peer-reviewed methods section.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does GLP-3RT take?\u003c\/strong\u003e\u003cbr\u003eIn the 48-week phase 2 obesity study, mean weight-change curves separated over months, with large effects reported by week 48 at higher doses. Early gastrointestinal symptoms, when they occur in incretin trials, often appear during escalation. Timelines are trial endpoints, not guarantees for any individual.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of GLP-3RT?\u003c\/strong\u003e\u003cbr\u003eGLP-3RT was designed as a long-acting molecule compatible with once-weekly subcutaneous dosing. Exact terminal half-life values should be taken from clinical pharmacology sections of sponsor publications rather than informal blogs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan GLP-3RT be stacked with other peptides?\u003c\/strong\u003e\u003cbr\u003ePivotal studies evaluate it alone within controlled backgrounds. Stacking with other GLP-1 or GIP agents is not an evidence-based research protocol and may compound mechanism-overlapping effects. Educational sites should discourage casual polypharmacy framing.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is GLP-3RT dosage calculated from a research vial?\u003c\/strong\u003e\u003cbr\u003emg_dose = concentration_mg_per_mL x mL_drawn. If a 20 mg vial is reconstituted with 2 mL, concentration is 10 mg\/mL, so 0.4 mL provides 4 mg. Use a calculator and dual-check units before any research preparation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eTriple-Hormone-Receptor Agonist GLP-3RT for Obesity - A Phase 2 Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36354040\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-3RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:33:01-07:00","created_at":"2026-07-26T21:11:12-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Nasal Sprays","tags":["15mL Nasal Spray","99%+ Purity","Nasal Sprays","Pre-Mixed"],"variants":[{"id":44076218482775,"title":"40mg","option1":"40mg","option2":null,"option3":null,"sku":"USPL-GLP-3RT-NASAL-40MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247768367191,"product_id":7712769769559,"position":1,"created_at":"2026-09-23T14:22:39-07:00","updated_at":"2026-09-23T14:22:40-07:00","alt":"GLP-3RT Nasal Spray 40mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-nasal-40mg.png?v=1790198560","variant_ids":[44076218482775]},"available":true,"price":"350.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769769559,"created_at":"2026-07-26T21:11:12-07:00","updated_at":"2026-09-23T23:45:45-07:00"},{"id":44076811845719,"title":"20mg","option1":"20mg","option2":null,"option3":null,"sku":"USPL-GLP-3RT-NASAL-20MG","requires_shipping":true,"taxable":true,"featured_image":{"id":36247768727639,"product_id":7712769769559,"position":2,"created_at":"2026-09-23T14:22:42-07:00","updated_at":"2026-09-23T14:22:44-07:00","alt":"GLP-3RT Nasal Spray 20mg — US Peptide Labs","width":1254,"height":1254,"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-nasal-20mg.png?v=1790198564","variant_ids":[44076811845719]},"available":true,"price":"220.00","grams":0,"compare_at_price":null,"position":2,"product_id":7712769769559,"created_at":"2026-07-27T03:10:18-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":36247768367191,"created_at":"2026-09-23T14:22:39-07:00","position":1,"updated_at":"2026-09-23T14:22:40-07:00","product_id":7712769769559,"variant_ids":[44076218482775],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-nasal-40mg.png?v=1790198560","width":1254,"height":1254},{"id":36247768727639,"created_at":"2026-09-23T14:22:42-07:00","position":2,"updated_at":"2026-09-23T14:22:44-07:00","product_id":7712769769559,"variant_ids":[44076811845719],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-3rt-nasal-20mg.png?v=1790198564","width":1254,"height":1254}],"options":[{"name":"Strength","position":1,"values":["40mg","20mg"]}]},{"id":7712769638487,"title":"5-Amino-1MQ","handle":"5-amino-1mq","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eSmall-molecule NNMT inhibitor (not a classical peptide)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003e5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide chain. It appears on peptide-education sites because the same research audiences shop metabolic compounds together, but chemically it is a methylquinolinium tool compound.\u003c\/p\u003e\u003cp\u003ePeer-reviewed work is primarily preclinical. In diet-induced obese mice, NNMT inhibition with 5-Amino-1MQ reduced adiposity and altered metabolic markers without requiring reduced food intake in key experiments. Follow-up studies combined NNMT inhibition with dietary change and examined microbiome and fat-mass endpoints.\u003c\/p\u003e\u003cp\u003eThere are no robust published human clinical dosage trials on PubMed comparable to approved metabolic drugs. Online capsule strengths are commercial research-chemical practices, not validated therapeutic regimens. Frame everything as laboratory reference information.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eNNMT methylates nicotinamide to 1-methylnicotinamide, influencing the NAD+ salvage pathway and methyl-donor balance. Inhibiting NNMT can raise NAD+ and SAM-related metabolic tone in adipose and other tissues in experimental systems. 5-Amino-1MQ is described as membrane-permeable and relatively selective versus several related methyltransferases, which is why it became a preferred in vivo NNMT tool compound.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eobesity and adipose biology\u003c\/li\u003e\n\u003cli\u003eNAD+ metabolism\u003c\/li\u003e\n\u003cli\u003eNNMT enzymology\u003c\/li\u003e\n\u003cli\u003ediet-drug combination metabolic research\u003c\/li\u003e\n\u003cli\u003emicrobiome-metabolism interactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eMetabolic disease labs, adipose biologists, and NAD+-pathway chemists are the core users. Longevity and body-composition research communities amplified interest after the mouse papers, which is why dosage queries spiked despite the thin human evidence base.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e20 mg\u003c\/td\u003e\n\u003ctd\u003ethree times daily (≈60 mg\/kg\/day total)\u003c\/td\u003e\n\u003ctd\u003esubcutaneous (preclinical)\u003c\/td\u003e\n\u003ctd\u003eDiet-induced obese mouse study (Neelakantan et al.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e32 mg\u003c\/td\u003e\n\u003ctd\u003eonce daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous (preclinical)\u003c\/td\u003e\n\u003ctd\u003eFollow-up DIO mouse work (Dimet-Wiley et al.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eAs a solid small molecule, store cool, dry, and light-protected in a tightly closed container. If a lab prepares a solution for animal work, follow solvent-specific stability (often aliquoted frozen); oral research capsules are kept sealed at controlled room temperature or per COA.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003ePublished stacking of true interest is with dietary intervention (calorie\/composition change), not with random peptide cocktails. Mechanistic neighbors include other NAD+-pathway tools (for example NMN\/NR research) and separate obesity agents, but combining them is a hypothesis generator rather than a validated protocol.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.6% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003e5-amino-1-methylquinolinium, 5A-1MQ, NNMTi, 5-amino-1-methylquinolinium iodide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort plasma window in mouse PK notes (rapid absorption; hours-scale coverage above IC50 reported in related profiling)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for 5-Amino-1MQ?\u003c\/strong\u003e\u003cbr\u003ePeer-reviewed dosages are mouse doses such as 20 mg\/kg SC three times daily or 32 mg\/kg SC once daily. Human clinical dose-finding trials are not established in the same literature set. Commercial capsule sizes should not be confused with proven therapeutic doses.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much BAC water for 5-Amino-1MQ?\u003c\/strong\u003e\u003cbr\u003eUsually not applicable. This compound is typically an oral research solid\/capsule or a solvent-dissolved animal-study preparation, not a bacteriostatic-water peptide reconstitution problem.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003e5-Amino-1MQ dosage per day?\u003c\/strong\u003e\u003cbr\u003eIn mice, total daily exposure in the flagship study was on the order of 60 mg\/kg\/day split t.i.d. That does not translate to a responsible human daily recommendation on an education page.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003e5-Amino-1MQ dosage chart?\u003c\/strong\u003e\u003cbr\u003eA research chart should list species, route, mg\/kg, and duration from primary papers. Charts that only show human capsule counts without citing clinical data overstate certainty.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is 5-Amino-1MQ half life?\u003c\/strong\u003e\u003cbr\u003eMouse pharmacokinetic profiling suggests rapid absorption and multi-hour presence above inhibitory concentrations after SC dosing; exact human half-life is not well established in peer-reviewed clinical PK papers.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan 5-Amino-1MQ be stacked?\u003c\/strong\u003e\u003cbr\u003eThe best-supported experimental 'stack' is with dietary modification in obese mouse models. Peptide stacking claims are mostly speculative and outside strong published evidence.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs 5-Amino-1MQ a peptide?\u003c\/strong\u003e\u003cbr\u003eNo. It is a small-molecule NNMT inhibitor. It is grouped with metabolic research compounds in commerce, which creates the naming confusion.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhy is it often sold as capsules?\u003c\/strong\u003e\u003cbr\u003eBecause it is a small molecule suited to oral solid handling in research-chemical markets. Note that key efficacy papers still relied on parenteral dosing in mice due to bioavailability considerations in that species.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29155147\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSelective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35013352\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eReduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:50-07:00","created_at":"2026-07-26T21:10:47-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Performance \u0026 Vitality","tags":["10mL Vial","99%+ Purity","Performance \u0026 Vitality","Third-Party Tested"],"variants":[{"id":44076218318935,"title":"50mg","option1":"50mg","option2":null,"option3":null,"sku":"USPL-5-AMINO-1MQ-50MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"62.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769638487,"created_at":"2026-07-26T21:10:47-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882880041047,"created_at":"2026-08-17T11:46:37-07:00","position":1,"updated_at":"2026-08-17T11:46:39-07:00","product_id":7712769638487,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-5-amino-1mq-50mg.png?v=1786992399","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["50mg"]}]},{"id":7712769605719,"title":"Semax","handle":"semax","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eSynthetic ACTH(4-10) heptapeptide nootropic \/ neuroprotective research peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSemax is a synthetic heptapeptide analogue of ACTH(4-10) with a Pro-Gly-Pro extension that improves stability relative to the native fragment. It has a long research history in Russian neuroscience for nootropic, neuroprotective, and cerebrovascular questions, with intranasal delivery as the dominant route.\u003c\/p\u003e\u003cp\u003eIndexed studies examine brain penetration after nasal dosing, membrane binding and biodegradation, BDNF-related signaling, and clinical-research use in acute ischemic stroke settings where multi-milligram daily intranasal totals were tested. Western large-scale replication is more limited than the domestic literature base.\u003c\/p\u003e\u003cp\u003eFor dosage education, distinguish animal mcg\/kg work, human stroke-trial milligram schedules, and lower-microgram nootropic research-chemical practices discussed online. Only documented literature ranges are emphasized here, under research-use-only framing.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eSemax does not act like a classical long-acting endocrine ACTH drug at therapeutic glucocorticoid doses. Research points to rapid CNS availability after intranasal dosing, specific binding interactions, proteolytic processing to shorter fragments, and downstream effects on neurotrophic systems including BDNF protein levels in animal work. Functional effects can outlast intact peptide concentrations because of gene-expression and network-level changes.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003enootropic and cognitive neuroscience\u003c\/li\u003e\n\u003cli\u003eischemic stroke recovery research\u003c\/li\u003e\n\u003cli\u003eBDNF and neurotrophic signaling\u003c\/li\u003e\n\u003cli\u003eintranasal peptide delivery\u003c\/li\u003e\n\u003cli\u003eACTH fragment structure-activity studies\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eNeuropharmacology labs, stroke-research clinicians in regions where Semax was developed, and blood-brain-barrier delivery groups are the primary audiences. Cognitive-enhancement communities drive search traffic, but legitimate content should stay anchored to peer-reviewed neuroscience rather than lifestyle dosing culture.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e12 mg – 18 mg\u003c\/td\u003e\n\u003ctd\u003edaily totals over 5–10 days\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eHuman acute ischemic stroke clinical research (intranasal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e200 mcg – 600 mcg\u003c\/td\u003e\n\u003ctd\u003e1–2 times daily\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eCommonly cited nootropic research-chemical discussions (not equivalent to stroke-trial dosing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized Semax is stored refrigerated or frozen, dry and dark. Reconstituted nasal research solutions are kept cold; sterile technique matters because the route is mucosal.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eResearch comparisons often place Semax beside Selank (another Russian regulatory peptide) when mapping anxiolytic vs nootropic peptide tools. Stroke papers evaluate it as an add-on to standard care rather than as part of a multi-peptide lifestyle stack. BDNF-pathway discussions sometimes reference other neurotrophic strategies at the mechanistic level only.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eMet-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) analogue, MEHFPGP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eRapid systemic degradation (minutes-scale peptide clearance reported); functional effects may last many hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for Semax?\u003c\/strong\u003e\u003cbr\u003eIt depends which literature you mean. Acute stroke research used roughly 12–18 mg\/day intranasally for several days. Secondary nootropic research discussions often cite a few hundred micrograms intranasally. Do not collapse those into one chart without labels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much BAC water for Semax?\u003c\/strong\u003e\u003cbr\u003eFor lyophilized powder, researchers pick a diluent volume that matches nasal spray or drop calibration—commonly 2–3 mL per multi-milligram vial. Some finished research preparations arrive already in solution.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax dosage per day?\u003c\/strong\u003e\u003cbr\u003eStroke-trial daily totals were in the low multi-milligram range. Cognitive research-chemical practice often discusses split intranasal mcg doses once or twice daily. Route in both cases is typically nasal, not subcutaneous.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSemax dosage chart?\u003c\/strong\u003e\u003cbr\u003eA careful chart separates (1) animal mcg\/kg data, (2) human stroke mg\/day protocols, and (3) lower mcg secondary references. Mixing them without context creates false precision.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is Semax half life?\u003c\/strong\u003e\u003cbr\u003eThe intact peptide is degraded quickly, yet behavioral or physiologic readouts in animal work can persist far longer, consistent with downstream neurotrophic signaling rather than continuous high plasma levels.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan Semax be stacked?\u003c\/strong\u003e\u003cbr\u003eResearch discourse sometimes pairs it conceptually with Selank or standard stroke therapy. Controlled evidence for elaborate multi-peptide stacks is limited; combinations remain experimental.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs Semax injected or nasal?\u003c\/strong\u003e\u003cbr\u003eThe dominant researched human route is intranasal. That is a major practical difference from most injectable research peptides on dosage pages.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs Semax an approved drug everywhere?\u003c\/strong\u003e\u003cbr\u003eIt has an established research\/clinical history in Russia and related literature. It is not broadly approved as a consumer nootropic in the United States; treat U.S. context as research-use education.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11517472\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16635254\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSemax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16523722\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9173745\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:47-07:00","created_at":"2026-07-26T21:10:40-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Cognitive \u0026 Mood","tags":["10mL Vial","99%+ Purity","Cognitive \u0026 Mood","Third-Party Tested"],"variants":[{"id":44076218286167,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-SEMAX-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"70.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769605719,"created_at":"2026-07-26T21:10:41-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882878632023,"created_at":"2026-08-17T11:46:26-07:00","position":1,"updated_at":"2026-08-17T11:46:28-07:00","product_id":7712769605719,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-semax-10mg.png?v=1786992388","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712769572951,"title":"Selank","handle":"selank","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003esynthetic heptapeptide anxiolytic research compound\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSelank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro sequence. Research has examined anxiolytic-like behavior, cognitive endpoints, cytokine signaling, monoamine systems, and gene-expression changes related to GABAergic neurotransmission. Much of the literature comes from Russian research groups and includes both clinical and preclinical designs.\u003c\/p\u003e\u003cp\u003eEducation content should keep Selank in research-use framing. It is not an FDA-approved drug product, and research-grade Selank is Research Use Only and not for human consumption. Reported ranges below reflect published human or animal study contexts where available and should not be treated as a protocol.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eSelank is studied as a tuftsin analog with neuroimmune and neuromodulatory effects. Published work links it to GABAergic gene-expression changes, monoamine metabolism, cytokine modulation, and anxiolytic-like behavioral outcomes. Unlike a single-receptor sedative model, Selank appears in the literature as a multi-pathway peptide with immune and CNS dimensions. That makes endpoint selection and comparator choice important in research design.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eanxiety-model behavior\u003c\/li\u003e\n\u003cli\u003eGABAergic signaling\u003c\/li\u003e\n\u003cli\u003eneuroimmune modulation\u003c\/li\u003e\n\u003cli\u003ecognitive research\u003c\/li\u003e\n\u003cli\u003ecytokine response\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSelank is studied by neuropharmacologists, behavioral neuroscience groups, psychopharmacology researchers, and immunology-focused peptide labs. Translational reviewers pay close attention to country of origin, formulation, route, and trial design.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mcg – 2.7 mg\u003c\/td\u003e\n\u003ctd\u003edaily in study protocols\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eClinical intranasal Selank literature commonly discusses sub-milligram to milligram daily exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e100 mcg – 300 mcg\u003c\/td\u003e\n\u003ctd\u003edaily course in animal protocols\u003c\/td\u003e\n\u003ctd\u003eintraperitoneal or intranasal in animal studies\u003c\/td\u003e\n\u003ctd\u003eRat behavioral research with Selank\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized Selank is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and handled aseptically.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eSelank is often discussed with Semax, nootropic compounds, or anxiolytic comparators, but combined CNS protocols can obscure whether changes reflect peptide effects, stress adaptation, or comparator pharmacology. Research designs should define behavioral endpoints and avoid converting regional clinical literature into general dosing advice.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eThr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP, tuftsin analog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eNot firmly established in widely cited human pharmacokinetic literature; Selank is generally discussed as a short peptide with effects that may outlast measurable exposure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for Selank\u003c\/strong\u003e\u003cbr\u003ePublished Selank discussions include intranasal human study contexts and animal mcg\/kg work. These are reference values only, not recommendations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for Selank\u003c\/strong\u003e\u003cbr\u003eSmall research vials are often modeled with 1-2 mL reconstitution volumes. The chosen volume sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily exposure in the literature depends on route, formulation, and study design. Research-grade Selank is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank dosage chart\u003c\/strong\u003e\u003cbr\u003eA responsible chart should separate human intranasal study references from animal per-kg experiments and clearly label all values as research context.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does Selank take\u003c\/strong\u003e\u003cbr\u003eBehavioral and subjective endpoints in studies are usually assessed over days to weeks, while molecular endpoints can be measured on shorter timelines.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSelank half life\u003c\/strong\u003e\u003cbr\u003eA practical human half-life is not well standardized in the mainstream literature. Effects may be discussed separately from simple plasma persistence.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan Selank be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied with comparators such as anxiolytic drugs or other peptides, but stacking complicates attribution and is not a use recommendation.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30255741\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003ePeptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25176261\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003e[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26924987\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:44-07:00","created_at":"2026-07-26T21:10:34-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Cognitive \u0026 Mood","tags":["10mL Vial","99%+ Purity","Cognitive \u0026 Mood","Third-Party Tested"],"variants":[{"id":44076218253399,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-SELANK-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"65.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769572951,"created_at":"2026-07-26T21:10:34-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882877059159,"created_at":"2026-08-17T11:46:15-07:00","position":1,"updated_at":"2026-08-17T11:46:17-07:00","product_id":7712769572951,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-selank-10mg.png?v=1786992377","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712769540183,"title":"Thymosin Alpha-1","handle":"thymosin-alpha-1","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eThymic immunomodulatory peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eThymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue and later produced synthetically. It has been investigated for decades as an immunomodulatory molecule that can influence T-cell maturation, dendritic-cell function, and innate immune signaling. In some countries a pharmaceutical form (thymalfasin) has been used clinically; that regulated product context is separate from bulk research-grade peptide supply.\u003c\/p\u003e\u003cp\u003eThe research literature spans viral immunology, sepsis adjunct models, vaccine-response biology, and cancer-immune interaction studies. Reviews summarize a large cumulative clinical-trial footprint and generally describe a favorable tolerability profile in studied settings, while also noting heterogeneity of indications and study quality.\u003c\/p\u003e\u003cp\u003eResearch-grade thymosin alpha-1 is Research Use Only. It is not an FDA-approved U.S. drug product for general therapeutic marketing in this RUO context, and it is not for human consumption. Dosage figures below are literature references for education only.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eTα1 interacts with innate immune pattern-recognition pathways, including Toll-like receptor-related signaling in dendritic cells and other antigen-presenting cells. Downstream effects reported in the literature include enhanced T-cell differentiation and function, modulation of cytokine patterns, support of NK-cell activity, and context-dependent restoration of immune competence in suppressed states. It is better described as a multi-node immune modulator than as a single-receptor hormone mimetic.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eT-cell and dendritic-cell immunology\u003c\/li\u003e\n\u003cli\u003ehost defense and viral immunology\u003c\/li\u003e\n\u003cli\u003esepsis and critical-illness immune tone\u003c\/li\u003e\n\u003cli\u003evaccine adjuvant biology\u003c\/li\u003e\n\u003cli\u003ecancer-immune interaction models\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eImmunologists, infectious-disease researchers, and translational oncology groups are the primary audience. Additional work appears in aging-immunity and vaccine-response laboratories interested in thymic peptide biology.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.6 mg – 3.2 mg\u003c\/td\u003e\n\u003ctd\u003etwice weekly\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eCommonly cited thymalfasin \/ Tα1 research and clinical-literature exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e900 mcg – 1.6 mg\u003c\/td\u003e\n\u003ctd\u003etwo to seven times weekly depending on protocol\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eAlternate research schedules summarized in reviews\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eKeep lyophilized Tα1 cold, dry, and light-protected. After reconstitution, refrigerate and handle as a labile peptide according to the laboratory beyond-use protocol.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eResearch designs sometimes evaluate thymosin alpha-1 alongside antivirals, checkpoint-oriented oncology regimens, or other immune modulators when the question is host-response augmentation. It is mechanistically distinct from tissue-repair peptides such as TB-500, so combinations are usually immunology-driven rather than recovery-stack driven.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.4% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eTα1, Thymalfasin, Thymosin α1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort plasma half-life (on the order of hours) reported; biologic immune effects are studied over longer courses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is thymosin alpha-1 peptide dosage in the literature?\u003c\/strong\u003e\u003cbr\u003eMany clinical and translational papers reference about 1.6 mg subcutaneously twice weekly for thymalfasin-style regimens. Other schedules exist; methods sections are the authoritative source.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs thymosin alpha-1 the same as TB-500?\u003c\/strong\u003e\u003cbr\u003eNo. Thymosin alpha-1 is an immunomodulatory thymic peptide. TB-500 relates to thymosin beta-4 actin biology. They are different molecules with different research stories.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat does thymosin alpha-1 do in immune models?\u003c\/strong\u003e\u003cbr\u003eLiterature describes effects on T-cell maturation, dendritic-cell activation via innate receptors, cytokine balance, and host-defense readiness in suppressed or challenged states.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs research-grade thymosin alpha-1 FDA-approved?\u003c\/strong\u003e\u003cbr\u003eResearch-grade material is RUO and not for human consumption. Pharmaceutical thymalfasin has been used in some countries under local regulatory frameworks, which is a separate product class.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhy do infectious-disease researchers care about Tα1?\u003c\/strong\u003e\u003cbr\u003eBecause multiple studies and reviews examine whether immune reconstitution or immune modulation with Tα1 changes host response in viral disease and sepsis models.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow is Tα1 usually supplied for laboratory work?\u003c\/strong\u003e\u003cbr\u003eAs lyophilized peptide in multi-milligram vials that are reconstituted before in vitro or in vivo experimental use.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDoes a short half-life mean it cannot be studied chronically?\u003c\/strong\u003e\u003cbr\u003eNo. Many protocols use repeated dosing over weeks because immune endpoints accumulate across a course even when plasma residence time per dose is short.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38308608\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eComprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33362999\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThymosin alpha 1: A comprehensive review of the literature.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27450734\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eImmune Modulation with Thymosin Alpha 1 Treatment.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25532482\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:41-07:00","created_at":"2026-07-26T21:10:27-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Anti-Aging \u0026 Longevity","tags":["10mL Vial","99%+ Purity","Anti-Aging \u0026 Longevity","Third-Party Tested"],"variants":[{"id":44076218220631,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-THYMOSIN-ALPHA-1-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"118.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769540183,"created_at":"2026-07-26T21:10:27-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882876862551,"created_at":"2026-08-17T11:46:04-07:00","position":1,"updated_at":"2026-08-17T11:46:06-07:00","product_id":7712769540183,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-thymosin-alpha-1-10mg.png?v=1786992366","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712769507415,"title":"Epitalon","handle":"epitalon","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003esynthetic pineal tetrapeptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEpitalon, also called Epithalon or AEDG, is a short tetrapeptide with the sequence Ala-Glu-Asp-Gly. Research interest comes from pineal-peptide biology, cellular aging models, telomerase activity, gene expression, circadian regulation, and lifespan experiments in animals and cell systems. The evidence base includes many older and region-specific studies, so careful source reading matters.\u003c\/p\u003e\u003cp\u003eEpitalon is not an FDA-approved drug product. Research-grade Epitalon is Research Use Only and is not for human consumption. Reported ranges below are drawn from experimental cell and animal contexts where dosing units can differ substantially from vial-based peptide math.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eEpitalon is studied for effects on telomerase activation, telomere dynamics, chromatin state, antioxidant systems, and pineal-regulated gene expression. Cell studies report changes in telomerase activity and telomere length, while animal studies examine lifespan markers, tumor incidence, and aging biomarkers. The mechanism is not reducible to one receptor target; it is usually framed through gene regulation and peptide bioregulation hypotheses.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003etelomerase activity\u003c\/li\u003e\n\u003cli\u003etelomere biology\u003c\/li\u003e\n\u003cli\u003eaging biomarkers\u003c\/li\u003e\n\u003cli\u003epineal peptide research\u003c\/li\u003e\n\u003cli\u003egene expression\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eEpitalon is studied by aging biologists, peptide bioregulation researchers, cell-culture groups, and gerontology-focused pharmacologists. Translational reviewers usually distinguish cell and animal findings from human claims because the clinical evidence is limited and heterogeneous.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0.01 mcg – 10 mcg\u003c\/td\u003e\n\u003ctd\u003ecell-culture exposure\u003c\/td\u003e\n\u003ctd\u003ein vitro\u003c\/td\u003e\n\u003ctd\u003eHuman somatic cell studies of Epithalon telomerase activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0.1 mcg – 1 mcg\u003c\/td\u003e\n\u003ctd\u003ecourse-based animal protocols\u003c\/td\u003e\n\u003ctd\u003eanimal-study injection routes\u003c\/td\u003e\n\u003ctd\u003eAnimal aging biomarker studies with Epitalon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized Epitalon is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and handled aseptically.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eEpitalon is often discussed with longevity-oriented compounds, NAD+ biology, or mitochondrial peptides, but those combinations can turn a cellular-aging question into an uninterpretable multi-variable protocol. Research designs should define whether the endpoint is telomerase, circadian markers, oxidative stress, or lifespan-model biology before adding other compounds.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eEpithalon, Epithalone, AEDG, Ala-Glu-Asp-Gly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eNot well established for practical human use; Epitalon literature focuses more on cellular and gene-expression outcomes than on clinical pharmacokinetics.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for Epitalon\u003c\/strong\u003e\u003cbr\u003ePublished Epitalon work includes cell-culture and animal-study exposures with different units. These are reference values, not personal dosing guidance.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for Epitalon\u003c\/strong\u003e\u003cbr\u003eResearch vials are often modeled with 1-2 mL reconstitution volumes. The right lab concentration depends on the experiment.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEpitalon dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily schedules discussed online often compress heterogeneous research into simple cycles. Literature-based content should cite the model, route, and endpoint.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEpitalon dosage chart\u003c\/strong\u003e\u003cbr\u003eA responsible chart should separate in vitro concentration data, animal exposure, and vial concentration math rather than presenting one universal chart.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does Epitalon take\u003c\/strong\u003e\u003cbr\u003eCellular endpoints such as gene expression can be measured over short lab windows, while aging-model outcomes require longer study designs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eEpitalon half life\u003c\/strong\u003e\u003cbr\u003eA practical human half-life is not well established in mainstream sources. Research often focuses on downstream cellular markers.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan Epitalon be stacked\u003c\/strong\u003e\u003cbr\u003eIt can be studied alongside other aging-biology variables, but stacking can make telomerase, redox, and circadian findings hard to attribute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40141333\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eOverview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12937682\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEpithalon peptide induces telomerase activity and telomere elongation in human somatic cells.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14501183\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:38-07:00","created_at":"2026-07-26T21:10:21-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Anti-Aging \u0026 Longevity","tags":["10mL Vial","99%+ Purity","Anti-Aging \u0026 Longevity","Third-Party Tested"],"variants":[{"id":44076218187863,"title":"100mg","option1":"100mg","option2":null,"option3":null,"sku":"USPL-EPITALON-100MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"180.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769507415,"created_at":"2026-07-26T21:10:21-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882876665943,"created_at":"2026-08-17T11:45:53-07:00","position":1,"updated_at":"2026-08-17T11:45:55-07:00","product_id":7712769507415,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-epitalon-100mg.png?v=1786992355","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["100mg"]}]},{"id":7712769474647,"title":"Melanotan II","handle":"melanotan-ii","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eSynthetic cyclic melanocortin receptor agonist\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eMelanotan II is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone. In research settings it is used to probe melanocortin receptors, especially MC1R-linked pigmentation pathways and central MC3R\/MC4R circuits involved in sexual function and energy balance. It is investigational and is discussed here strictly as a research compound.\u003c\/p\u003e\u003cp\u003eSmall human pilot studies in the 1990s characterized subcutaneous dosing, pigmentation changes, and dose-limiting effects such as nausea and yawning\/stretching complexes. Separate controlled work examined erectile responses in men with psychogenic erectile dysfunction. Those papers are historical clinical-research documents, not modern use guides.\u003c\/p\u003e\u003cp\u003eBecause Melanotan II sits in a compliance-sensitive category often misused in cosmetic tanning communities, educational content must stay inside research-use-only language. No cosmetic self-administration guidance is provided or implied.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eMelanotan II is a non-selective melanocortin receptor agonist. MC1R activation on melanocytes increases eumelanin synthesis, which is why pigmentation endpoints appear in early trials. Central MC3R\/MC4R engagement helps explain observed effects on sexual behavior and appetite-related readouts in experimental models. Cyclic structure improves potency and enzymatic stability versus linear native α-MSH fragments.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin receptor pharmacology\u003c\/li\u003e\n\u003cli\u003epigmentation biology\u003c\/li\u003e\n\u003cli\u003esexual function neuroendocrine research\u003c\/li\u003e\n\u003cli\u003eenergy balance and appetite models\u003c\/li\u003e\n\u003cli\u003epeptide PK assay development\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eDermatology-adjacent pigment labs, melanocortin neuropharmacology groups, and sexual-medicine research units are the historical audiences. Regulatory, toxicology, and analytical chemists also study it because unregulated cosmetic channels created public-health surveillance questions. This profile is for research literacy only.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e700 mcg – 2.1 mg\u003c\/td\u003e\n\u003ctd\u003eweekday research dosing over short courses\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePilot phase I subcutaneous research (Dorr et al.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003einvestigational single\/short-term SC dosing\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003ePsychogenic ED pharmacodynamic study (Wessells et al.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eStore lyophilized Melanotan II frozen or refrigerated per COA, dry and light-protected. After bacteriostatic-water reconstitution, keep refrigerated and protected from light; discard according to lab stability policy.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eResearch literature more often studies Melanotan II alone as a melanocortin probe than as part of a modern peptide stack. Mechanistic comparisons are made with afamelanotide\/Melanotan I (linear NDP-MSH) and with selective MC4R agonists used in metabolic or sexual-function research. No cosmetic stacking discussion is appropriate or provided.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.3% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eMelanotan-2, MT-II, MT2, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eShort plasma residence in rodent PK work (tens of minutes reported); biologic pigment effects outlast plasma levels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for Melanotan 2 in published research?\u003c\/strong\u003e\u003cbr\u003eHuman pilot research commonly referenced about 0.025 mg\/kg subcutaneously (on the order of 1–2 mg for many adult body weights) under clinical supervision. Those are historical trial exposures for research characterization only.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much BAC water for Melanotan 2?\u003c\/strong\u003e\u003cbr\u003eFor a typical 10 mg research vial, 2–3 mL bacteriostatic water is a common laboratory dilution so that mcg\/kg calculations are syringe-measurable. Exact volume is protocol-dependent.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eMelanotan 2 dosage per day?\u003c\/strong\u003e\u003cbr\u003eEarly phase I designs used repeated weekday subcutaneous doses over about two weeks rather than an indefinite daily lifestyle schedule. Published human work is short-course and supervised.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eMelanotan 2 dosage chart?\u003c\/strong\u003e\u003cbr\u003eResearch charts, when used, convert mg\/kg trial doses into mcg for a stated body mass and diluent volume. They are literature translation tools, not tanning guides.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is Melanotan 2 half life?\u003c\/strong\u003e\u003cbr\u003eRodent pharmacokinetic reports describe rapid plasma clearance, while pigmentation biology can continue after the peptide is no longer measurable in blood. Human half-life characterization remains limited compared with approved melanocortin drugs.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan Melanotan 2 be stacked?\u003c\/strong\u003e\u003cbr\u003eControlled research generally evaluates it as a single melanocortin agonist. Combining research chemicals for cosmetic tanning is outside the scope of legitimate RUO education and is not advised here.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eIs Melanotan II the same as afamelanotide?\u003c\/strong\u003e\u003cbr\u003eNo. Afamelanotide (Melanotan I \/ NDP-MSH) is a related but distinct linear analogue with a different clinical development path. Melanotan II is the cyclic heptapeptide MT-II.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhy is Melanotan II discussed as research-only?\u003c\/strong\u003e\u003cbr\u003eIt is not an FDA-approved tanning or sexual-function drug, and unsupervised cosmetic use has raised safety and quality concerns. Educational content therefore stays inside research-literature framing.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9679884\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eSynthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7981427\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eA comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:35-07:00","created_at":"2026-07-26T21:10:14-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Performance \u0026 Vitality","tags":["10mL Vial","99%+ Purity","Performance \u0026 Vitality","Third-Party Tested"],"variants":[{"id":44076218155095,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-MELANOTAN-II-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"55.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769474647,"created_at":"2026-07-26T21:10:14-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882876207191,"created_at":"2026-08-17T11:45:42-07:00","position":1,"updated_at":"2026-08-17T11:45:44-07:00","product_id":7712769474647,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-melanotan-ii-10mg.png?v=1786992344","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712769441879,"title":"PT-141","handle":"pt-141","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003emelanocortin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.\u003c\/p\u003e\u003cp\u003eBremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003ePT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emelanocortin signaling\u003c\/li\u003e\n\u003cli\u003eMC4R neurobiology\u003c\/li\u003e\n\u003cli\u003esexual arousal pharmacodynamics\u003c\/li\u003e\n\u003cli\u003eCNS peptide signaling\u003c\/li\u003e\n\u003cli\u003epeptide pharmacokinetics\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003ePT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mcg – 10 mg\u003c\/td\u003e\n\u003ctd\u003esingle study administration\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous PT-141 clinical pharmacology study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003esingle crossover study administration\u003c\/td\u003e\n\u003ctd\u003eintranasal\u003c\/td\u003e\n\u003ctd\u003eIntranasal PT-141 plus sildenafil study in men with erectile dysfunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1.75 mg\u003c\/td\u003e\n\u003ctd\u003eas labeled for the approved product\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eFDA-approved bremelanotide product label context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eResearch-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003ePT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003ebremelanotide, PT-141, melanocortin receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eBremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for PT-141\u003c\/strong\u003e\u003cbr\u003ePublished PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for PT-141\u003c\/strong\u003e\u003cbr\u003eReconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage per day\u003c\/strong\u003e\u003cbr\u003ePT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does PT-141 take\u003c\/strong\u003e\u003cbr\u003eClinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ePT-141 half life\u003c\/strong\u003e\u003cbr\u003eBremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan PT-141 be stacked\u003c\/strong\u003e\u003cbr\u003eIt has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16839319\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15833522\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:32-07:00","created_at":"2026-07-26T21:10:08-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Performance \u0026 Vitality","tags":["10mL Vial","99%+ Purity","Performance \u0026 Vitality","Third-Party Tested"],"variants":[{"id":44076218122327,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-PT-141-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"55.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769441879,"created_at":"2026-07-26T21:10:08-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882876076119,"created_at":"2026-08-17T11:45:32-07:00","position":1,"updated_at":"2026-08-17T11:45:34-07:00","product_id":7712769441879,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-pt-141-10mg.png?v=1786992334","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]},{"id":7712769409111,"title":"SS-31","handle":"ss-31","body_html":"\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003eMitochondria-targeting tetrapeptide (cardiolipin-binding)\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eSS-31, known clinically as elamipretide, is a small aromatic-cationic tetrapeptide designed to target the inner mitochondrial membrane. Foundational work showed high-affinity interaction with cardiolipin, protection of cristae architecture, and improved bioenergetics in ischemic and stressed mitochondria.\u003c\/p\u003e\u003cp\u003eThe molecule has progressed into multiple clinical research programs under the elamipretide name, including studies in primary mitochondrial disease, cardiac indications, Barth syndrome, and other mitochondria-linked conditions. Published doses in later subcutaneous programs commonly reference 40 mg daily in specific trial protocols, while earlier intravenous work used mg\/kg\/hour infusions. Parallel academic papers map its protein-interaction landscape and aging-mitochondria effects.\u003c\/p\u003e\u003cp\u003eEducational dosage pages should prioritize peer-reviewed trial methods and mechanistic papers. Research-supply vials marketed as SS-31 are not automatically equivalent to clinical trial product. Keep research-use framing explicit and avoid disease-cure language.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eSS-31 concentrates at the inner mitochondrial membrane through electrostatic and hydrophobic interaction with cardiolipin. Binding is reported to stabilize cristae, reduce cardiolipin peroxidation, improve electron-transport efficiency, and limit pathological reactive oxygen species generation. Cytochrome c peroxidase activity and apoptotic signaling cascades are among the downstream processes discussed in the literature. Net experimental readouts include preserved ATP production and improved organ function in ischemia-reperfusion and aging models.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003emitochondrial bioenergetics\u003c\/li\u003e\n\u003cli\u003eischemia-reperfusion models\u003c\/li\u003e\n\u003cli\u003ecardiolipin biology\u003c\/li\u003e\n\u003cli\u003eprimary mitochondrial disease research\u003c\/li\u003e\n\u003cli\u003ecardiac and skeletal muscle energetics\u003c\/li\u003e\n\u003cli\u003eaging biology\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eMitochondrial medicine groups, cardiology research teams, and rare-disease investigators (including Barth syndrome programs) form the core audience. Basic scientists use SS-31 as a tool compound to probe cardiolipin-dependent membrane organization. This is a bioenergetics research community more than a cosmetic-peptide audience.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e4 mg – 40 mg\u003c\/td\u003e\n\u003ctd\u003eonce daily\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eElamipretide clinical research programs using daily subcutaneous administration (trial-specific)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eno single figure reported\u003c\/td\u003e\n\u003ctd\u003einfusion per protocol\u003c\/td\u003e\n\u003ctd\u003eintravenous\u003c\/td\u003e\n\u003ctd\u003eEarly intravenous dose-escalation \/ infusion studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eLyophilized research material: refrigerate or freeze per COA, protect from light. Reconstituted solutions: refrigerate, minimize agitation and freeze-thaw, and adhere to supplier or pharmacy beyond-use dating.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eClinical protocols study elamipretide as a targeted mitochondrial agent, sometimes on top of standard disease-specific care, not mixed into broad mito stacks with uncharacterized peptides. Academic comparisons may include other mitochondria-targeted antioxidants as separate arms. Avoid implying synergistic cure claims for combinations.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e10mL Vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eElamipretide, MTP-131, Bendavia, D-Arg-Dmt-Lys-Phe-NH2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eOn the order of hours in clinical pharmacology descriptions for elamipretide (route- and study-dependent; confirm in the specific PK publication)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWhat is the dosage for SS-31 \/ elamipretide?\u003c\/strong\u003e\u003cbr\u003eIn several subcutaneous clinical research programs, 40 mg once daily is a prominently documented regimen. Earlier studies also tested lower SC amounts and IV mg\/kg\/hour infusions. Those numbers are trial doses for defined populations, not general self-administration guidance.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow much bac water for SS-31?\u003c\/strong\u003e\u003cbr\u003eMatch diluent to vial strength so that the intended mg dose is a measurable fraction of a milliliter. Example: 50 mg vial + 2 mL bac water = 25 mg\/mL, so 1.6 mL approximates 40 mg. Plan concentration carefully for research pharmacy workflows.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSS-31 dosage per day\u003c\/strong\u003e\u003cbr\u003eDaily subcutaneous dosing is the pattern used in multiple elamipretide programs. Community research vials sometimes discuss lower milligram amounts; distinguish those informal figures from peer-reviewed 40 mg daily protocols.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSS-31 dosage chart\u003c\/strong\u003e\u003cbr\u003eBuild charts from concentration (mg\/mL) to mL drawn for target mg. Include a note separating clinical-trial 40 mg anchors from any lower research-catalog experiments. Unit confusion between mcg and mg is a common error with this compound.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHow long does SS-31 take?\u003c\/strong\u003e\u003cbr\u003eTrial durations span weeks to months depending on indication and endpoint (bioenergetic biomarkers versus clinical scales). Preclinical ischemia models can show acute mitochondrial effects. No single consumer timeline applies.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat is the half life of SS-31?\u003c\/strong\u003e\u003cbr\u003eElamipretide PK supports daily dosing in SC programs, implying a half-life measured in hours rather than days. Use the clinical pharmacology section of the relevant study for numeric values.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eCan SS-31 be stacked?\u003c\/strong\u003e\u003cbr\u003eFormal studies keep it as a focused mitochondrial intervention. Combining with other research peptides without a protocol adds noise. If co-interventions exist, they are usually standard-of-care medications defined by the disease under study.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23813215\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24117165\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eFirst-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32554501\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eMitochondrial protein interaction landscape of SS-31.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38237649\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eApplication research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","published_at":"2026-07-26T21:32:29-07:00","created_at":"2026-07-26T21:10:01-07:00","updated_at":"2026-09-23T23:45:45-07:00","vendor":"US Peptide Labs","product_type":"Anti-Aging \u0026 Longevity","tags":["10mL Vial","99%+ Purity","Anti-Aging \u0026 Longevity","Third-Party Tested"],"variants":[{"id":44076218089559,"title":"10mg","option1":"10mg","option2":null,"option3":null,"sku":"USPL-SS-31-10MG","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"price":"60.00","grams":0,"compare_at_price":null,"position":1,"product_id":7712769409111,"created_at":"2026-07-26T21:10:02-07:00","updated_at":"2026-09-23T23:45:45-07:00"}],"images":[{"id":35882875813975,"created_at":"2026-08-17T11:45:21-07:00","position":1,"updated_at":"2026-08-17T11:45:23-07:00","product_id":7712769409111,"variant_ids":[],"src":"https:\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/vial-ss-31-10mg.png?v=1786992323","width":1600,"height":1600}],"options":[{"name":"Strength","position":1,"values":["10mg"]}]}]}